Carolinetsh的个人主页 - 老虎社区

Carolinetsh

暂无个人介绍

IP属地：未知

377关注

31粉丝

0主题

0勋章

2021-11-13

Just sold mine

Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.

2021-11-11

$Pfizer(PFE)$Up up up

2021-11-09

$Apple(AAPL)$Drop again

2021-11-08

$Alibaba(BABA)$When will it goes up to $200?

2021-11-07

Pfizer is the way to go

Will Moderna and Pfizer Continue to Lead After the COVID-19 Pandemic Ends?

2021-11-06

Up up up

抱歉，原内容已删除

2021-11-04

Please go up up up

抱歉，原内容已删除

2021-11-04

Dun drop please

抱歉，原内容已删除

2021-11-03

Good

Pfizer Raises Covid-19 Vaccine Forecast as Sales More Than Double

2021-10-27

$Alibaba(BABA)$What happens again?

2021-10-14

Please like

Can Pfizer Beat Moderna in mRNA Vaccines?

2021-09-13

Like please

Buy or Sell Apple Stock Ahead of iPhone Event?

2021-09-12

Please like

BlackBerry Has a Chance at Turning Into a Growth Stock

2021-09-08

Please like

Apple to Hold Sept. 14 Event for New iPhone Line, Other Devices

2021-09-05

$Alibaba(BABA)$Buy buy buy

2021-09-04

Like and comment

After criticism, Apple says it will delay child safety updates

2021-09-03

Like please

抱歉，原内容已删除

2021-09-02

Good

抱歉，原内容已删除

2021-08-29

Please like

抱歉，原内容已删除

2021-08-27

Please like

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3582507638581570","uuid":"3582507638581570","gmtCreate":1619499677057,"gmtModify":1619499677057,"name":"Carolinetsh","pinyin":"carolinetsh","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":31,"headSize":377,"tweetSize":95,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.11","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":873062154,"gmtCreate":1636803354904,"gmtModify":1636803355129,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"Just sold mine&nbsp;","listText":"Just sold mine&nbsp;","text":"Just sold mine","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/873062154","repostId":"1102251183","repostType":2,"repost":{"id":"1102251183","kind":"news","pubTimestamp":1636772424,"share":"https://www.laohu8.com/m/news/1102251183?lang=&edition=full","pubTime":"2021-11-13 11:00","market":"us","language":"en","title":"Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.","url":"https://stock-news.laohu8.com/highlight/detail?id=1102251183","media":"Barrons","summary":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo","content":"<p>Pfizer’s&nbsp;chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p>\n<p>“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p>\n<p>Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p>\n<p>Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p>\n<p>In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p>\n<p>The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p>\n<p>Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like&nbsp;Johnson &amp; Johnson&nbsp;(JNJ) and&nbsp;Eli Lilly&nbsp;(LLY).</p>\n<p>The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p>\n<p>The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p>\n<p>The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p>\n<p>While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech&nbsp;BioNTech&nbsp;(BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p>\n<p>In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p>\n<p>The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p>\n<p>“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p>\n<p>Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p>\n<p>“[Pfizer’s] pharmaceutical R&amp;D is better than people had thought.”</p>\n<p>The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p>\n<p>“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p>\n<p>Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from&nbsp;Merck&nbsp;(MRK).</p>\n<p>“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&amp;D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p>\n<p>Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p>\n<p>“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p>\n<p>That makes a bet on Pfizer a long-term play. In the meantime, the experience of&nbsp;Moderna&nbsp;(MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p>\n<p>Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p>\n<p>Moderna shares are down more than 40% over the past three months.</p>\n<p>As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p>\n<p>When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p>\n<p>That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p>\n<p>Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p>\n<p>Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p>\n<p>An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-13 11:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that...</p>\n\n<a href=\"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102251183","content_text":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.\n“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.\nTwo years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.\nBourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.\nIn a cover story in November 2019, Barron’s argued that Bourla and Dolsten could pull it off.\nThe new antiviral data reaffirms the case for Pfizer that Barron’s made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.\nPfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).\nThe Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.\nThe worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.\nThe success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.\nWhile Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.\nIn the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.\nThe antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.\n“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.\nDolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.\n“[Pfizer’s] pharmaceutical R&D is better than people had thought.”\nThe protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.\n“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.\nPfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).\n“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.\nChen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.\n“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”\nThat makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.\nBiden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”\nModerna shares are down more than 40% over the past three months.\nAs the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling Barron’s that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.\nWhen it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.\nThat contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.\nDolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”\nSuch a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.\nAn aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.","news_type":1},"isVote":1,"tweetType":1,"viewCount":676,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":870638605,"gmtCreate":1636608708026,"gmtModify":1636608708239,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>Up up up","listText":"<a href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>Up up up","text":"$Pfizer(PFE)$Up up up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/870638605","isVote":1,"tweetType":1,"viewCount":781,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":844729171,"gmtCreate":1636462121695,"gmtModify":1636462122268,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Drop again&nbsp;","listText":"<a href=\"https://laohu8.com/S/AAPL\">$Apple(AAPL)$</a>Drop again&nbsp;","text":"$Apple(AAPL)$Drop again","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844729171","isVote":1,"tweetType":1,"viewCount":559,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":845536378,"gmtCreate":1636349180795,"gmtModify":1636349181234,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BABA\">$Alibaba(BABA)$</a>When will it goes up to $200?","listText":"<a href=\"https://laohu8.com/S/BABA\">$Alibaba(BABA)$</a>When will it goes up to $200?","text":"$Alibaba(BABA)$When will it goes up to $200?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/845536378","isVote":1,"tweetType":1,"viewCount":774,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":845983675,"gmtCreate":1636264427454,"gmtModify":1636264478168,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"Pfizer is the way to go","listText":"Pfizer is the way to go","text":"Pfizer is the way to go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/845983675","repostId":"2181742241","repostType":4,"repost":{"id":"2181742241","kind":"highlight","pubTimestamp":1636200000,"share":"https://www.laohu8.com/m/news/2181742241?lang=&edition=full","pubTime":"2021-11-06 20:00","market":"us","language":"en","title":"Will Moderna and Pfizer Continue to Lead After the COVID-19 Pandemic Ends?","url":"https://stock-news.laohu8.com/highlight/detail?id=2181742241","media":"Motley Fool","summary":"Probably, but there will be room for other players in the COVID-19 vaccine market, too.","content":"<p><b>Pfizer</b> (NYSE:PFE) and <b>Moderna</b> (NASDAQ:MRNA) are dominating the global COVID-19 vaccine market. But can they continue to do so once the pandemic is over? In this <i>Motley Fool Live</i> video <b>recorded on Oct. 27</b>, Fool contributors Keith Speights and Brian Orelli address this question, as well as the potential for other companies to succeed.</p>\n<p><b>Keith Speights:</b> Now, here's <a href=\"https://laohu8.com/S/AONE.U\">one</a> that I think that we both can talk about here. Joe asked, \"Where do you see the COVID market going if the pandemic becomes an epidemic?\" He also says, \"Will Moderna and Pfizer&nbsp;continue to lead? Where will <b>CureVac</b> (NASDAQ:CVAC) and <b>Novavax</b> (NASDAQ:NVAX) fit in in such a scenario?\" That's a good question.</p>\n<p><b>Brian Orelli:</b> I wonder whether he means endemic which means it's around all the time. Pandemic would be it comes and then goes. Endemic means it's like the flu. It's around every year, you are never going to actually get rid of it.</p>\n<p>I think Moderna and Pfizer are definitely going to continue to lead because they have such a head start, not just in the ability, doctors having experience with it, but also their ability to manufacture quite a bit of it. I think they will definitely continue to lead.</p>\n<p>Is there room for Novavax and CureVac? I think there probably is.</p>\n<p>I think that it's really going to depend on whether we need more boosters. We don't really know what our memory B cells are going to do and what the virus is going to do. That's basically, the virus mutates enough, then our memory B cells can't take care of the virus then it will be a problem. If the virus doesn't mutate enough and then we're all vaccinated and we have fairly good memory B cells, well then we get infected with the coronavirus and SARS-CoV-2 and our bodies just take care of it and maybe we get sniffles or something.</p>\n<p>But it's not a major issue. We don't worry about the cold. I don't think we'd have much problems. I don't think there was going to be that big of a market for boosters if people aren't dying from COVID-19.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Will Moderna and Pfizer Continue to Lead After the COVID-19 Pandemic Ends?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWill Moderna and Pfizer Continue to Lead After the COVID-19 Pandemic Ends?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-06 20:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/06/will-moderna-and-pfizer-continue-to-lead-after-the/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) are dominating the global COVID-19 vaccine market. But can they continue to do so once the pandemic is over? In this Motley Fool Live video recorded on Oct....</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/06/will-moderna-and-pfizer-continue-to-lead-after-the/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/11/06/will-moderna-and-pfizer-continue-to-lead-after-the/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2181742241","content_text":"Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) are dominating the global COVID-19 vaccine market. But can they continue to do so once the pandemic is over? In this Motley Fool Live video recorded on Oct. 27, Fool contributors Keith Speights and Brian Orelli address this question, as well as the potential for other companies to succeed.\nKeith Speights: Now, here's one that I think that we both can talk about here. Joe asked, \"Where do you see the COVID market going if the pandemic becomes an epidemic?\" He also says, \"Will Moderna and Pfizer continue to lead? Where will CureVac (NASDAQ:CVAC) and Novavax (NASDAQ:NVAX) fit in in such a scenario?\" That's a good question.\nBrian Orelli: I wonder whether he means endemic which means it's around all the time. Pandemic would be it comes and then goes. Endemic means it's like the flu. It's around every year, you are never going to actually get rid of it.\nI think Moderna and Pfizer are definitely going to continue to lead because they have such a head start, not just in the ability, doctors having experience with it, but also their ability to manufacture quite a bit of it. I think they will definitely continue to lead.\nIs there room for Novavax and CureVac? I think there probably is.\nI think that it's really going to depend on whether we need more boosters. We don't really know what our memory B cells are going to do and what the virus is going to do. That's basically, the virus mutates enough, then our memory B cells can't take care of the virus then it will be a problem. If the virus doesn't mutate enough and then we're all vaccinated and we have fairly good memory B cells, well then we get infected with the coronavirus and SARS-CoV-2 and our bodies just take care of it and maybe we get sniffles or something.\nBut it's not a major issue. We don't worry about the cold. I don't think we'd have much problems. I don't think there was going to be that big of a market for boosters if people aren't dying from COVID-19.","news_type":1},"isVote":1,"tweetType":1,"viewCount":977,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":842277559,"gmtCreate":1636192322891,"gmtModify":1636192323359,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"Up up up","listText":"Up up up","text":"Up up up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842277559","repostId":"1173813098","repostType":4,"isVote":1,"tweetType":1,"viewCount":1084,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":846098273,"gmtCreate":1636033996643,"gmtModify":1636034004896,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"Please go up up up","listText":"Please go up up up","text":"Please go up up up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/846098273","repostId":"1107936396","repostType":4,"isVote":1,"tweetType":1,"viewCount":979,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":848406158,"gmtCreate":1636016403992,"gmtModify":1636016404375,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"Dun drop please","listText":"Dun drop please","text":"Dun drop please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/848406158","repostId":"1167064150","repostType":4,"isVote":1,"tweetType":1,"viewCount":748,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":841587163,"gmtCreate":1635926115553,"gmtModify":1635926115709,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"Good&nbsp;","listText":"Good&nbsp;","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/841587163","repostId":"1167449573","repostType":4,"repost":{"id":"1167449573","kind":"news","pubTimestamp":1635922924,"share":"https://www.laohu8.com/m/news/1167449573?lang=&edition=full","pubTime":"2021-11-03 15:02","market":"us","language":"en","title":"Pfizer Raises Covid-19 Vaccine Forecast as Sales More Than Double","url":"https://stock-news.laohu8.com/highlight/detail?id=1167449573","media":"The Wall Street Journal","summary":"Shot’s $13 billion revenue provides the biggest contribution to drugmaker’s third-quarter sales\nOf t","content":"<p>Shot’s $13 billion revenue provides the biggest contribution to drugmaker’s third-quarter sales</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/85ed5523396f63a03a4597730fa17ed8\" tg-width=\"1290\" tg-height=\"859\" referrerpolicy=\"no-referrer\"><span>Of the nearly 200 million Americans who have been fully vaccinated, more than half got Pfizer shots.</span></p>\n<p>Pfizer&nbsp;Inc.&nbsp;increased its forecast for sales of its Covid-19 vaccine this year to about $36 billion, a roughly 7% boost that comes as the U.S. prepares to distribute the shot to 28 million children ages 5 to 11 years old.</p>\n<p>The New York-based drugmaker said its sales projection for the vaccine it developed with partner&nbsp;BioNTech&nbsp;SE takes into account expected deliveries of about 2.3 billion vaccine doses this year. The companies have&nbsp;grown their capabilities&nbsp;for manufacturing doses, and are&nbsp;working with other firms&nbsp;overseas to produce doses.</p>\n<p>The vaccine’s revenue of $13 billion was the biggest contributor to Pfizer’s third-quarter sales of about $24 billion, which more than doubled year over year. More than 75% of vaccine sales this year are from international sales, as the vaccine has reached 152 countries, Pfizer Chief Executive Albert Bourla said on an earnings call.</p>\n<p>The vaccine remains in global demand in countries that are receiving initial supplies and others that&nbsp;have begun booster campaigns, as well as those that have yet to receive any supplies at all. The U.S. has authorized additional shots of the vaccine for many high-risk adults and last week cleared use of the vaccine for children&nbsp;as young as 5 years old.</p>\n<p>In the U.S., the vaccine is expected to be available to the young children as soon as Wednesday in some locations, because the Centers for Disease Control and Prevention on Tuesday night endorsed use of the shot in the children. The agency’s endorsement was the last step before the vaccines could be administered, after the Food and Drug Administration authorized use&nbsp;outside clinical trials&nbsp;last week. Booster shots of the vaccine were cleared in September for many high-risk adults.</p>\n<p>Pfizer is planning to produce about four billion doses next year, but has secured orders for 1.7 billion doses. The number of orders shows it is meeting demand, and low-income countries should move to strike supply deals before wealthy countries, to avoid falling behind as they did in the world’s initial vaccine rollout, Mr. Bourla said in an interview.</p>\n<p>“We are already going way above what we forecast is needed based on the orders we have,” Mr. Bourla said. “If there are orders we will make more next year.”</p>\n<p>While data from Pfizer and other researchers have shown an&nbsp;additional dose might increase protection, a trial studying a fourth dose of the vaccine could start next spring, about a year after trial subjects in its studies received third doses, said Pfizer Chief Scientific Officer Mikael Dolsten in an interview.</p>\n<p>That could lead to study results in time for people to get a fourth dose when they get flu shots.</p>\n<p>“It’s really to prepare for what we think is the very likely need for annual revaccinations,” he said.</p>\n<p>The company recently said that a third dose was found in a large study&nbsp;to be safe and highly protective&nbsp;against symptomatic Covid-19.</p>\n<p>The vaccine’s revenue of $13 billion was the biggest contributor to Pfizer’s third-quarter sales of about $24 billion, which more than doubled year over year. More than 75% of vaccine sales this year are from international sales, as the vaccine has reached 152 countries, Mr. Bourla said.</p>\n<p>Pfizer said it expects initial results on its experimental Covid-19 antiviral, which is in late-stage testing, by the end of the first quarter of 2022. Researchers are studying the drug in both vaccinated and unvaccinated people, and low-risk individuals, which could differentiate it from a promising antiviral from&nbsp;Merck&amp; Co. and Ridgeback Biotherapeutics LP under review by the Food and Drug Administration.</p>\n<p>The company has begun providing scientific data to the FDA, although it hasn’t formally requested authorization. Pfizer will be able to deliver doses this year, if authorized, Mr. Bourla said.</p>\n<p>Pfizer expects as many as 150 million adults globally could need the antiviral because of infections and close contacts, said Pfizer Biopharmaceuticals President Angela Hwang. She said that there is potential for long-term sales and for government contracts for stockpiling.</p>\n<p>Pfizer forecast $29 billion in sales next year off the 1.7 billion doses, reflecting the durability of long-term sales and efforts by countries to curb the spread of the virus in winter months. Mr. Bourla said many countries will be purchasing pediatric doses. Next year’s revenue is likely to be even higher because the forecast reflects supply agreements signed through mid-October.</p>\n<p>Should the sales materialize, they would make the Pfizer-BioNTech vaccine the bestselling pharmaceutical product of all time. The world’s top-selling prescription drug in recent years has been&nbsp;AbbVie&nbsp;Inc.’s&nbsp;anti-inflammatory drug Humira, which sold nearly $20 billion in 2018.</p>\n<p>Pfizer splits vaccine sales with BioNTech.</p>\n<p>The outlook for Pfizer’s vaccine reflects the preference of the vaccine over ones from its rivals. Nearly 200 million Americans have been fully vaccinated, with more than half receiving Pfizer-BioNTech shots. Most of the rest received the vaccine from&nbsp;Moderna&nbsp;Inc.&nbsp;that uses a similar mRNA-based technology.</p>\n<p>Pfizer has also distributed two billion doses so far and is on track to produce three billion doses.</p>\n<p>Mr. Bourla in the interview urged poor countries to secure supply—at discounted or not-for-profit prices—for next year, and that he wants to avoid repeating another year in which they lagged behind wealthier countries. He said he hopes the World Health Organization and Covax can help.</p>\n<p>The Covax program, run by a number of organizations including Unicef and the WHO, was created with the intention to offer rich and poor nations equitable access to vaccines.</p>\n<p>Mr. Bourla said he has sent letters to countries asking them to place orders, and said they should be more proactive than in the past.</p>\n<p>“Some governments are better than others,” he said. “That’s the problem.”</p>\n<p>Pfizer and other vaccine makers are facing criticism from countries, public-health officials and drug-access advocates for not supplying enough doses to low- and middle-income countries. Some countries lacked funds to secure deals with companies or the knowledge to make their own shots, forcing them to rely on the Covax program. Countries with supply deals have also been hampered by inadequate infrastructure needed to refrigerate vaccines.</p>\n<p>Only 3.7% of people in low-income countries&nbsp;have received at least one dose of a Covid-19 vaccine, according to Our World in Data. Some critics have proposed governments waive intellectual-property rights to spur production, an idea rejected by vaccine makers.</p>\n<p>The Pfizer-BioNTech vaccine&nbsp;is expected to be available soon&nbsp;in the U.S. to children as young as 5 years old, after U.S. health authorities last week authorized its emergency use as the first Covid-19 shot for the youngsters. The shot is fully approved for people 16 years and up, and is cleared for emergency use in children 12 and older.</p>\n<p>U.S. regulators have cleared boosters for people vaccinated with the Pfizer-BioNTech vaccine at least six months after their second dose, as long as they are seniors or at high risk because of underlying medical conditions or their workplace. The regulators have since broadened availability of boosters to people who received Moderna or&nbsp;Johnson &amp; Johnson.</p>\n<p>The Pfizer-BioNTech vaccine has advanced through clinical trials and regulatory hurdles faster than rival shots cleared for use in adults.</p>\n<p>Initial results from a clinical study of the Pfizer-BioNTech vaccine in children 2 to 4 years&nbsp;are expected by the end of the year, while data for children 6 months to under 2 should be in by the end of next quarter, Dr. Dolsten said.</p>\n<p>Moderna said recently it won’t seek approval for its vaccine’s use in young children until the FDA clears&nbsp;the shots for teenagers. Johnson &amp; Johnson, the third vaccine cleared for use in the U.S., is studying the shot in teens but hasn’t started studying it yet in younger children.</p>\n<p>Pfizer also raised its overall financial guidance for the year, forecasting sales of $81 billion to $82 billion, and adjusted earnings of $4.13 a share to $4.18 a share. It attributed the increase to both vaccine and nonvaccine momentum.</p>\n<p>Excluding the Covid-19 vaccine, sales of Pfizer’s other drugs rose 7%. Oncology drug sales rose 12% to more than $3 billion, as sales jumped on breast-cancer treatment Ibrance and prostate-cancer drug Xtandi. Revenue for blood thinner rose 21% to more than $1.3 billion.</p>\n<p>Stripping out one-time items, the company’s adjusted third-quarter profit was $1.34 a share. Wall Street analysts had predicted $22.58 billion in revenue and adjusted earnings of $1.08 a share.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Raises Covid-19 Vaccine Forecast as Sales More Than Double</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Raises Covid-19 Vaccine Forecast as Sales More Than Double\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-03 15:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.wsj.com/articles/pfizer-ups-covid-19-vaccine-forecast-as-sales-more-than-double-11635853492?mod=lead_feature_below_a_pos1><strong>The Wall Street Journal</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shot’s $13 billion revenue provides the biggest contribution to drugmaker’s third-quarter sales\nOf the nearly 200 million Americans who have been fully vaccinated, more than half got Pfizer shots.\n...</p>\n\n<a href=\"https://www.wsj.com/articles/pfizer-ups-covid-19-vaccine-forecast-as-sales-more-than-double-11635853492?mod=lead_feature_below_a_pos1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.wsj.com/articles/pfizer-ups-covid-19-vaccine-forecast-as-sales-more-than-double-11635853492?mod=lead_feature_below_a_pos1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167449573","content_text":"Shot’s $13 billion revenue provides the biggest contribution to drugmaker’s third-quarter sales\nOf the nearly 200 million Americans who have been fully vaccinated, more than half got Pfizer shots.\nPfizer Inc. increased its forecast for sales of its Covid-19 vaccine this year to about $36 billion, a roughly 7% boost that comes as the U.S. prepares to distribute the shot to 28 million children ages 5 to 11 years old.\nThe New York-based drugmaker said its sales projection for the vaccine it developed with partner BioNTech SE takes into account expected deliveries of about 2.3 billion vaccine doses this year. The companies have grown their capabilities for manufacturing doses, and are working with other firms overseas to produce doses.\nThe vaccine’s revenue of $13 billion was the biggest contributor to Pfizer’s third-quarter sales of about $24 billion, which more than doubled year over year. More than 75% of vaccine sales this year are from international sales, as the vaccine has reached 152 countries, Pfizer Chief Executive Albert Bourla said on an earnings call.\nThe vaccine remains in global demand in countries that are receiving initial supplies and others that have begun booster campaigns, as well as those that have yet to receive any supplies at all. The U.S. has authorized additional shots of the vaccine for many high-risk adults and last week cleared use of the vaccine for children as young as 5 years old.\nIn the U.S., the vaccine is expected to be available to the young children as soon as Wednesday in some locations, because the Centers for Disease Control and Prevention on Tuesday night endorsed use of the shot in the children. The agency’s endorsement was the last step before the vaccines could be administered, after the Food and Drug Administration authorized use outside clinical trials last week. Booster shots of the vaccine were cleared in September for many high-risk adults.\nPfizer is planning to produce about four billion doses next year, but has secured orders for 1.7 billion doses. The number of orders shows it is meeting demand, and low-income countries should move to strike supply deals before wealthy countries, to avoid falling behind as they did in the world’s initial vaccine rollout, Mr. Bourla said in an interview.\n“We are already going way above what we forecast is needed based on the orders we have,” Mr. Bourla said. “If there are orders we will make more next year.”\nWhile data from Pfizer and other researchers have shown an additional dose might increase protection, a trial studying a fourth dose of the vaccine could start next spring, about a year after trial subjects in its studies received third doses, said Pfizer Chief Scientific Officer Mikael Dolsten in an interview.\nThat could lead to study results in time for people to get a fourth dose when they get flu shots.\n“It’s really to prepare for what we think is the very likely need for annual revaccinations,” he said.\nThe company recently said that a third dose was found in a large study to be safe and highly protective against symptomatic Covid-19.\nThe vaccine’s revenue of $13 billion was the biggest contributor to Pfizer’s third-quarter sales of about $24 billion, which more than doubled year over year. More than 75% of vaccine sales this year are from international sales, as the vaccine has reached 152 countries, Mr. Bourla said.\nPfizer said it expects initial results on its experimental Covid-19 antiviral, which is in late-stage testing, by the end of the first quarter of 2022. Researchers are studying the drug in both vaccinated and unvaccinated people, and low-risk individuals, which could differentiate it from a promising antiviral from Merck& Co. and Ridgeback Biotherapeutics LP under review by the Food and Drug Administration.\nThe company has begun providing scientific data to the FDA, although it hasn’t formally requested authorization. Pfizer will be able to deliver doses this year, if authorized, Mr. Bourla said.\nPfizer expects as many as 150 million adults globally could need the antiviral because of infections and close contacts, said Pfizer Biopharmaceuticals President Angela Hwang. She said that there is potential for long-term sales and for government contracts for stockpiling.\nPfizer forecast $29 billion in sales next year off the 1.7 billion doses, reflecting the durability of long-term sales and efforts by countries to curb the spread of the virus in winter months. Mr. Bourla said many countries will be purchasing pediatric doses. Next year’s revenue is likely to be even higher because the forecast reflects supply agreements signed through mid-October.\nShould the sales materialize, they would make the Pfizer-BioNTech vaccine the bestselling pharmaceutical product of all time. The world’s top-selling prescription drug in recent years has been AbbVie Inc.’s anti-inflammatory drug Humira, which sold nearly $20 billion in 2018.\nPfizer splits vaccine sales with BioNTech.\nThe outlook for Pfizer’s vaccine reflects the preference of the vaccine over ones from its rivals. Nearly 200 million Americans have been fully vaccinated, with more than half receiving Pfizer-BioNTech shots. Most of the rest received the vaccine from Moderna Inc. that uses a similar mRNA-based technology.\nPfizer has also distributed two billion doses so far and is on track to produce three billion doses.\nMr. Bourla in the interview urged poor countries to secure supply—at discounted or not-for-profit prices—for next year, and that he wants to avoid repeating another year in which they lagged behind wealthier countries. He said he hopes the World Health Organization and Covax can help.\nThe Covax program, run by a number of organizations including Unicef and the WHO, was created with the intention to offer rich and poor nations equitable access to vaccines.\nMr. Bourla said he has sent letters to countries asking them to place orders, and said they should be more proactive than in the past.\n“Some governments are better than others,” he said. “That’s the problem.”\nPfizer and other vaccine makers are facing criticism from countries, public-health officials and drug-access advocates for not supplying enough doses to low- and middle-income countries. Some countries lacked funds to secure deals with companies or the knowledge to make their own shots, forcing them to rely on the Covax program. Countries with supply deals have also been hampered by inadequate infrastructure needed to refrigerate vaccines.\nOnly 3.7% of people in low-income countries have received at least one dose of a Covid-19 vaccine, according to Our World in Data. Some critics have proposed governments waive intellectual-property rights to spur production, an idea rejected by vaccine makers.\nThe Pfizer-BioNTech vaccine is expected to be available soon in the U.S. to children as young as 5 years old, after U.S. health authorities last week authorized its emergency use as the first Covid-19 shot for the youngsters. The shot is fully approved for people 16 years and up, and is cleared for emergency use in children 12 and older.\nU.S. regulators have cleared boosters for people vaccinated with the Pfizer-BioNTech vaccine at least six months after their second dose, as long as they are seniors or at high risk because of underlying medical conditions or their workplace. The regulators have since broadened availability of boosters to people who received Moderna or Johnson & Johnson.\nThe Pfizer-BioNTech vaccine has advanced through clinical trials and regulatory hurdles faster than rival shots cleared for use in adults.\nInitial results from a clinical study of the Pfizer-BioNTech vaccine in children 2 to 4 years are expected by the end of the year, while data for children 6 months to under 2 should be in by the end of next quarter, Dr. Dolsten said.\nModerna said recently it won’t seek approval for its vaccine’s use in young children until the FDA clears the shots for teenagers. Johnson & Johnson, the third vaccine cleared for use in the U.S., is studying the shot in teens but hasn’t started studying it yet in younger children.\nPfizer also raised its overall financial guidance for the year, forecasting sales of $81 billion to $82 billion, and adjusted earnings of $4.13 a share to $4.18 a share. It attributed the increase to both vaccine and nonvaccine momentum.\nExcluding the Covid-19 vaccine, sales of Pfizer’s other drugs rose 7%. Oncology drug sales rose 12% to more than $3 billion, as sales jumped on breast-cancer treatment Ibrance and prostate-cancer drug Xtandi. Revenue for blood thinner rose 21% to more than $1.3 billion.\nStripping out one-time items, the company’s adjusted third-quarter profit was $1.34 a share. Wall Street analysts had predicted $22.58 billion in revenue and adjusted earnings of $1.08 a share.","news_type":1},"isVote":1,"tweetType":1,"viewCount":916,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":852552146,"gmtCreate":1635293000201,"gmtModify":1635293070740,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BABA\">$Alibaba(BABA)$</a>What happens again?","listText":"<a href=\"https://laohu8.com/S/BABA\">$Alibaba(BABA)$</a>What happens again?","text":"$Alibaba(BABA)$What happens again?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/852552146","isVote":1,"tweetType":1,"viewCount":648,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":822766853,"gmtCreate":1634172057278,"gmtModify":1634172057429,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"Please like","listText":"Please like","text":"Please like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/822766853","repostId":"2175547781","repostType":4,"repost":{"id":"2175547781","kind":"highlight","pubTimestamp":1634136326,"share":"https://www.laohu8.com/m/news/2175547781?lang=&edition=full","pubTime":"2021-10-13 22:45","market":"us","language":"en","title":"Can Pfizer Beat Moderna in mRNA Vaccines?","url":"https://stock-news.laohu8.com/highlight/detail?id=2175547781","media":"Motley Fool","summary":"Pfizer is expanding beyond its coronavirus vaccine.","content":"<p>Before the pandemic, most of us probably didn't spend a lot of time thinking about messenger RNA (mRNA). But <b>Moderna</b> (NASDAQ:MRNA) changed that. The biotech company brought mRNA to center stage when it began developing its coronavirus vaccine. The vaccine uses mRNA to instruct the body's cells to produce a specific protein. From here, our immune system creates antibodies necessary to block infection.</p>\n<p>Moderna didn't develop this technology overnight, though. The company has been working on it for more than a decade. In fact, it has mRNA candidates in the pipeline for a variety of therapeutic areas. Its coronavirus vaccine rival <b>Pfizer</b> (NYSE:PFE) is a newcomer to mRNA. It got into the business through partnerships with Germany's <b>BioNTech</b>. But Pfizer has big mRNA plans. Now the question is: Should Moderna be worried?</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F646369%2Fgettyimages-healthcare-worker-prepares-vaccine-dose.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Pfizer's BioNTech partnership</h2>\n<p>So, let's look at what Pfizer is doing in the mRNA space. Pfizer initially partnered with BioNTech for the development of mRNA flu vaccines back in 2018. Fast forward to 2020. As the pandemic deepened, Pfizer entered into a new agreement with its biotech partner. It would co-develop and co-commercialize BioNTech's investigational mRNA coronavirus vaccine.</p>\n<p>Today, the vaccine generates billions of dollars for Pfizer and BioNTech. The companies predict they'll split profit on more than $33 billion in coronavirus vaccine revenue this year.</p>\n<p>Meanwhile, Pfizer isn't limiting its mRNA business to the coronavirus product. It recently launched a phase 1 trial of an mRNA vaccine candidate for flu. This is in the context of its partnership with BioNTech. If the candidate makes it to commercialization, Pfizer would pay BioNTech royalties.</p>\n<p>But Pfizer isn't stopping with flu, either. The big pharma player says it will develop mRNA candidates for other respiratory illnesses and will expand into oncology and genetic diseases.</p>\n<h2>A potential blockbuster</h2>\n<p>Now, let's take a look at Moderna's situation. Since mRNA isn't new to Moderna, the company is well beyond the planning stages. It has 37 programs in the pipeline, and 22 are in clinical studies. Like Pfizer, Moderna also recently began a clinical trial for a flu vaccine candidate.</p>\n<p>Importantly, Moderna has five candidates in phase 2 studies and <a href=\"https://laohu8.com/S/AONE.U\">one</a> candidate ready for phase 3. It expects to launch a phase 3 study of its cytomegalovirus vaccine candidate this year. That could&nbsp;be a billion-dollar product.</p>\n<p>From a timeline perspective, Moderna remains ahead of Pfizer in the development of potential mRNA products. It's also likely Moderna, after years of focusing on this specific area, might have gained expertise that will be difficult to beat.</p>\n<p>Of course, on the subject of timelines, you may think back to the coronavirus vaccine race. Moderna launched the very first clinical trial of a vaccine candidate. Yet the Pfizer/BioNTech team not only caught up, but also beat Moderna to market. Could that happen again? It's not likely.</p>\n<p>First of all, both coronavirus candidates were at about the same stage of development. And second, urgent need during the pandemic meant it was easy to quickly enroll clinical trials. In non-pandemic times, people don't always leap at the opportunity to join a clinical trial. So the enrollment process may slow things down.</p>\n<h2>$15 billion in cash</h2>\n<p>Last year, Pfizer's experience and resources allowed it to move quickly to the top in the coronavirus vaccine market. But Moderna has learned a thing or two as it's signed contracts and produced and delivered vaccines this year. It has built up financial resources, too. Moderna's cash position is about $15 billion. Pfizer's cash, cash equivalents, and short-term investments total $21.7 billion. Pfizer has the edge, but not by much. Both clearly have what it takes financially to advance their programs and launch potential products.</p>\n<p>Does this mean Pfizer isn't a threat to Moderna? Not necessarily. Failure can happen at any clinical-trial stage. If a Moderna candidate fails in the clinic, but Pfizer's rival candidate succeeds even a few years later, then Pfizer wins. That could happen for certain programs. And it could ensure Pfizer a position in this exciting market.</p>\n<p>But overall, I don't expect Pfizer to beat Moderna at mRNA. The size of Moderna's mRNA pipeline and the number of late-stage candidates make that unlikely. If all goes smoothly for Moderna during most clinical trials, this biotech company is likely to maintain its reign in the world of mRNA.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Can Pfizer Beat Moderna in mRNA Vaccines?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCan Pfizer Beat Moderna in mRNA Vaccines?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-13 22:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/13/can-pfizer-beat-moderna-in-mrna-vaccines/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Before the pandemic, most of us probably didn't spend a lot of time thinking about messenger RNA (mRNA). But Moderna (NASDAQ:MRNA) changed that. The biotech company brought mRNA to center stage when ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/13/can-pfizer-beat-moderna-in-mrna-vaccines/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/10/13/can-pfizer-beat-moderna-in-mrna-vaccines/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2175547781","content_text":"Before the pandemic, most of us probably didn't spend a lot of time thinking about messenger RNA (mRNA). But Moderna (NASDAQ:MRNA) changed that. The biotech company brought mRNA to center stage when it began developing its coronavirus vaccine. The vaccine uses mRNA to instruct the body's cells to produce a specific protein. From here, our immune system creates antibodies necessary to block infection.\nModerna didn't develop this technology overnight, though. The company has been working on it for more than a decade. In fact, it has mRNA candidates in the pipeline for a variety of therapeutic areas. Its coronavirus vaccine rival Pfizer (NYSE:PFE) is a newcomer to mRNA. It got into the business through partnerships with Germany's BioNTech. But Pfizer has big mRNA plans. Now the question is: Should Moderna be worried?\nImage source: Getty Images.\nPfizer's BioNTech partnership\nSo, let's look at what Pfizer is doing in the mRNA space. Pfizer initially partnered with BioNTech for the development of mRNA flu vaccines back in 2018. Fast forward to 2020. As the pandemic deepened, Pfizer entered into a new agreement with its biotech partner. It would co-develop and co-commercialize BioNTech's investigational mRNA coronavirus vaccine.\nToday, the vaccine generates billions of dollars for Pfizer and BioNTech. The companies predict they'll split profit on more than $33 billion in coronavirus vaccine revenue this year.\nMeanwhile, Pfizer isn't limiting its mRNA business to the coronavirus product. It recently launched a phase 1 trial of an mRNA vaccine candidate for flu. This is in the context of its partnership with BioNTech. If the candidate makes it to commercialization, Pfizer would pay BioNTech royalties.\nBut Pfizer isn't stopping with flu, either. The big pharma player says it will develop mRNA candidates for other respiratory illnesses and will expand into oncology and genetic diseases.\nA potential blockbuster\nNow, let's take a look at Moderna's situation. Since mRNA isn't new to Moderna, the company is well beyond the planning stages. It has 37 programs in the pipeline, and 22 are in clinical studies. Like Pfizer, Moderna also recently began a clinical trial for a flu vaccine candidate.\nImportantly, Moderna has five candidates in phase 2 studies and one candidate ready for phase 3. It expects to launch a phase 3 study of its cytomegalovirus vaccine candidate this year. That could be a billion-dollar product.\nFrom a timeline perspective, Moderna remains ahead of Pfizer in the development of potential mRNA products. It's also likely Moderna, after years of focusing on this specific area, might have gained expertise that will be difficult to beat.\nOf course, on the subject of timelines, you may think back to the coronavirus vaccine race. Moderna launched the very first clinical trial of a vaccine candidate. Yet the Pfizer/BioNTech team not only caught up, but also beat Moderna to market. Could that happen again? It's not likely.\nFirst of all, both coronavirus candidates were at about the same stage of development. And second, urgent need during the pandemic meant it was easy to quickly enroll clinical trials. In non-pandemic times, people don't always leap at the opportunity to join a clinical trial. So the enrollment process may slow things down.\n$15 billion in cash\nLast year, Pfizer's experience and resources allowed it to move quickly to the top in the coronavirus vaccine market. But Moderna has learned a thing or two as it's signed contracts and produced and delivered vaccines this year. It has built up financial resources, too. Moderna's cash position is about $15 billion. Pfizer's cash, cash equivalents, and short-term investments total $21.7 billion. Pfizer has the edge, but not by much. Both clearly have what it takes financially to advance their programs and launch potential products.\nDoes this mean Pfizer isn't a threat to Moderna? Not necessarily. Failure can happen at any clinical-trial stage. If a Moderna candidate fails in the clinic, but Pfizer's rival candidate succeeds even a few years later, then Pfizer wins. That could happen for certain programs. And it could ensure Pfizer a position in this exciting market.\nBut overall, I don't expect Pfizer to beat Moderna at mRNA. The size of Moderna's mRNA pipeline and the number of late-stage candidates make that unlikely. If all goes smoothly for Moderna during most clinical trials, this biotech company is likely to maintain its reign in the world of mRNA.","news_type":1},"isVote":1,"tweetType":1,"viewCount":205,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":888878331,"gmtCreate":1631490837623,"gmtModify":1632810232026,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"Like please","listText":"Like please","text":"Like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/888878331","repostId":"1101906502","repostType":4,"repost":{"id":"1101906502","kind":"news","pubTimestamp":1631407634,"share":"https://www.laohu8.com/m/news/1101906502?lang=&edition=full","pubTime":"2021-09-12 08:47","market":"us","language":"en","title":"Buy or Sell Apple Stock Ahead of iPhone Event?","url":"https://stock-news.laohu8.com/highlight/detail?id=1101906502","media":"TheStreet","summary":"Apple stock was under pressure on Friday, with its iPhone event just days away. Here's how to trade the stock from here.Shares of Apple Report fell $5.10, or 3.31%, to end at $148.97 Friday, as investors digested recent news and prepared for the iPhone event next week.On Sept. 14, the company will hold a virtual event to introduce the new device. Dubbed “California Streaming,” it’s expected that Apple will introduce its new iPhone and Apple Watch.However, Apple remains in the news for other reas","content":"<p>Apple stock was under pressure on Friday, with its iPhone event just days away. Here's how to trade the stock from here.</p>\n<p>Shares of Apple&nbsp;Report&nbsp;fell $5.10, or 3.31%, to end at $148.97 Friday, as investors digested recent news and prepared for the iPhone event next week.</p>\n<p>On Sept. 14, the company will&nbsp;hold a virtual event to introduce&nbsp;the new device. Dubbed “California Streaming,” it’s expected that Apple will introduce its new iPhone and Apple Watch.</p>\n<p>However, Apple remains in the news for other reasons, too.</p>\n<p>After hitting new highs earlier this week, the stock declined Friday after news of a court ruling&nbsp;in its case with Epic Games.</p>\n<p>That’s alongside a report that was published by well-known Morgan Stanley analyst Katy Huberty, who made the case that Apple stock&nbsp;is “compelling” ahead of its upcoming event.</p>\n<p>Like I said, it’s a lot of information for investors to digest. Let’s take a look at how the charts are setting up.</p>\n<p><b>Trading Apple Stock</b></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/bd94f6dcfc32af44a4ae542425f3c92f\" tg-width=\"700\" tg-height=\"429\" width=\"100%\" height=\"auto\"><span>Daily chart of Apple stock.</span></p>\n<p>Each time Apple has reported earnings this year, it has resulted in a selloff. Unfortunately, those selloffs would come right as the stock was at or near all-time highs. Those events are marked on the chart with blue arrows.</p>\n<p>It was even more frustrating that Apple&nbsp;blew out analysts’ expectations each time, yet the stock sold off anyway.</p>\n<p>However, rather than a massive dip following the most recent report, the stock only pulled back to the $145 area, near the prior high. It also held the 21-day moving average as support.</p>\n<p>The stock has since pushed up through $150 and earlier this week, hit new all-time highs.</p>\n<p>For now, we’re getting a dip back down to the key $150 area and the 21-day moving average. Aggressive bulls can buy this dip ahead of the company’s event on Tuesday.</p>\n<p>If we break Friday’s low, investors may consider stopping out of the trade and buying on a potentially larger dip down to the 50-day moving average or the $145 area.</p>\n<p>Below $145 may put the $138 level and the 200-day moving average in play.</p>\n<p>Should Apple trade up through the all-time high at $157.26, the 161.8% extension is in play up near $160. Above that mark could put the $172 to $175 zone on the table, depending on how investors react to the event.</p>\n<p>For what it’s worth, September is by far Apple’s worst-performing month, up just three of the last 11 years for the month.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Buy or Sell Apple Stock Ahead of iPhone Event?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBuy or Sell Apple Stock Ahead of iPhone Event?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-12 08:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/trading-apple-aapl-stock-ahead-of-iphone13-event><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Apple stock was under pressure on Friday, with its iPhone event just days away. Here's how to trade the stock from here.\nShares of Apple Report fell $5.10, or 3.31%, to end at $148.97 Friday, as ...</p>\n\n<a href=\"https://www.thestreet.com/investing/trading-apple-aapl-stock-ahead-of-iphone13-event\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.thestreet.com/investing/trading-apple-aapl-stock-ahead-of-iphone13-event","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101906502","content_text":"Apple stock was under pressure on Friday, with its iPhone event just days away. Here's how to trade the stock from here.\nShares of Apple Report fell $5.10, or 3.31%, to end at $148.97 Friday, as investors digested recent news and prepared for the iPhone event next week.\nOn Sept. 14, the company will hold a virtual event to introduce the new device. Dubbed “California Streaming,” it’s expected that Apple will introduce its new iPhone and Apple Watch.\nHowever, Apple remains in the news for other reasons, too.\nAfter hitting new highs earlier this week, the stock declined Friday after news of a court ruling in its case with Epic Games.\nThat’s alongside a report that was published by well-known Morgan Stanley analyst Katy Huberty, who made the case that Apple stock is “compelling” ahead of its upcoming event.\nLike I said, it’s a lot of information for investors to digest. Let’s take a look at how the charts are setting up.\nTrading Apple Stock\nDaily chart of Apple stock.\nEach time Apple has reported earnings this year, it has resulted in a selloff. Unfortunately, those selloffs would come right as the stock was at or near all-time highs. Those events are marked on the chart with blue arrows.\nIt was even more frustrating that Apple blew out analysts’ expectations each time, yet the stock sold off anyway.\nHowever, rather than a massive dip following the most recent report, the stock only pulled back to the $145 area, near the prior high. It also held the 21-day moving average as support.\nThe stock has since pushed up through $150 and earlier this week, hit new all-time highs.\nFor now, we’re getting a dip back down to the key $150 area and the 21-day moving average. Aggressive bulls can buy this dip ahead of the company’s event on Tuesday.\nIf we break Friday’s low, investors may consider stopping out of the trade and buying on a potentially larger dip down to the 50-day moving average or the $145 area.\nBelow $145 may put the $138 level and the 200-day moving average in play.\nShould Apple trade up through the all-time high at $157.26, the 161.8% extension is in play up near $160. Above that mark could put the $172 to $175 zone on the table, depending on how investors react to the event.\nFor what it’s worth, September is by far Apple’s worst-performing month, up just three of the last 11 years for the month.","news_type":1},"isVote":1,"tweetType":1,"viewCount":130,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":888931114,"gmtCreate":1631420162138,"gmtModify":1632810513987,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"Please like&nbsp;","listText":"Please like&nbsp;","text":"Please like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/888931114","repostId":"1127699574","repostType":4,"repost":{"id":"1127699574","kind":"news","pubTimestamp":1631328152,"share":"https://www.laohu8.com/m/news/1127699574?lang=&edition=full","pubTime":"2021-09-11 10:42","market":"us","language":"en","title":"BlackBerry Has a Chance at Turning Into a Growth Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1127699574","media":"InvestorPlace","summary":"BB stock could be worth 30% more, assuming the company turns FCF positive next fiscal year","content":"<p><b>Blackberry</b>&nbsp;(NYSE:<b><u>BB</u></b>), the automotive embedded software company, produced positive free cash flow (FCF)&nbsp;of $74 million&nbsp;last fiscal year ending May 31. But its fiscal&nbsp;Q1 showed a loss of $35 million in FCF. This didn’t do anything to help BB stock. If fell from a near-term peak of $15.88 on June 3 (before the June 24 Q1 results) to $9.56 on Aug. 19. The stock could be near a trough now.</p>\n<p>I still believe that&nbsp;as I wrote on June 4, BB stock could be worth $20.91 per share, assuming its FCF turns positive this year. All eyes will therefore be on its upcoming Sept. 22 fiscal Q2 earnings release. Investors will want to see if revenue is growing and the company achieves positive FCF.</p>\n<p>For example, last quarter ending May 31 revenue fell by 15.5% year-over-year (YOY) from $206 million last year to $174 million this quarter. In fact, it was also down by 17.1% from the prior quarter as well.</p>\n<p>That is almost like a curse for a stock like Blackberry. Investors and analysts want to see positive growth on a steady YoY and quarter-over-quarter (QOQ) basis. This probably explains why the stock fell so much.</p>\n<p><b>Where This Leaves BlackBerry</b></p>\n<p>Last year BlackBerry produced $893 million in revenue, but for this fiscal year ending May 2022 analysts still see lower sales at $781.6 million. However, they also expect a recovery by May 2023 to $954.1 million. But is the market willing to wait until then? That is why the upcoming fiscal Q2 2022 earnings release will be so important. Investors want to see if the company is back on a growth track.</p>\n<p>If it is, then the likelihood that it can produce positive free cash flow for the year will increase, and this will help BB stock recover.</p>\n<p>For example, as I pointed out in my last article, BlackBerry reported FCF during Q4 of $49 million. This was a huge 23.33% of its $210 million in revenue during the quarter. Assuming it can pull off the same thing next year the company could make $222.3 million in FCF that year. That is based on 23.33% of sales of $954.1 million.</p>\n<p>However, to be more conservative let’s assume that it can only make half of that or an 11.5% FCF margin. That lowers its forecast FCF to $109.7 million. Moreover, its present value using a 10% discount rate and a year and a half in the future is 86.68% times this FCF number. That lowers it to $95.1 million.</p>\n<p><b>What BlackBerry Stock Could Be Worth</b></p>\n<p>If we use an FCF yield of between 1% we can calculate the company’s ongoing value. This is calculated by dividing the free cash flow estimates by its FCF yield ratio.</p>\n<p>For example, using $95.1 million in FCF forecast for Blackberry in 2023 brings its value to $9.51 billion. This is 55.7% over today’s market value for Blackberry of $6.109 billion.</p>\n<p>And if we use a 1.5% FCF yield, the target market value falls to $6.34 billion (i.e., $95.1/0.015=$6.34b). That is just 3.78% over today’s price.</p>\n<p>Therefore, BB stock has a target value between 3.78% and 55.7% over today’s price. The average is 29.74%, or basically 30% over today’s price of $10.73. That puts its value at $13.95 per share (estimate rounded to $14).</p>\n<p><b>What to do With BB Stock</b></p>\n<p>Analysts are not very positive about BB stock. For example, seven analysts surveyed by Refinitiv (reported by&nbsp;<i>Yahoo! Finance</i>) have an average target price of $8.36. That implies a potential drop of 22% from today’s price.</p>\n<p>Another survey by&nbsp;<i>TipRanks.com</i>&nbsp;says that four analysts have an&nbsp;average price of $9.50or 11.5% below today’s price. However, nine Wall Street analysts surveyed by&nbsp;<i>Seeking Alpha</i>&nbsp;have an&nbsp;average target of $8.19, or 23.7% below today.</p>\n<p>So the average of all three of these surveys is a price of $8.68, or 19% lower. I would not be too bothered by this though. Analysts have a tendency to raise their price targets after the stock has already risen.</p>\n<p>Enterprising investors who are willing to anticipate more positive results for the year ending May 2023 (and probably before that) could see the stock rise 30% to $13.95 per share.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BlackBerry Has a Chance at Turning Into a Growth Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBlackBerry Has a Chance at Turning Into a Growth Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-11 10:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/09/bb-stock-could-turn-around-next-fiscal-year-if-revenue-rebounds-as-analysts-forecast/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Blackberry (NYSE:BB), the automotive embedded software company, produced positive free cash flow (FCF) of $74 million last fiscal year ending May 31. But its fiscal Q1 showed a loss of $35 million in ...</p>\n\n<a href=\"https://investorplace.com/2021/09/bb-stock-could-turn-around-next-fiscal-year-if-revenue-rebounds-as-analysts-forecast/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BB":"黑莓"},"source_url":"https://investorplace.com/2021/09/bb-stock-could-turn-around-next-fiscal-year-if-revenue-rebounds-as-analysts-forecast/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1127699574","content_text":"Blackberry (NYSE:BB), the automotive embedded software company, produced positive free cash flow (FCF) of $74 million last fiscal year ending May 31. But its fiscal Q1 showed a loss of $35 million in FCF. This didn’t do anything to help BB stock. If fell from a near-term peak of $15.88 on June 3 (before the June 24 Q1 results) to $9.56 on Aug. 19. The stock could be near a trough now.\nI still believe that as I wrote on June 4, BB stock could be worth $20.91 per share, assuming its FCF turns positive this year. All eyes will therefore be on its upcoming Sept. 22 fiscal Q2 earnings release. Investors will want to see if revenue is growing and the company achieves positive FCF.\nFor example, last quarter ending May 31 revenue fell by 15.5% year-over-year (YOY) from $206 million last year to $174 million this quarter. In fact, it was also down by 17.1% from the prior quarter as well.\nThat is almost like a curse for a stock like Blackberry. Investors and analysts want to see positive growth on a steady YoY and quarter-over-quarter (QOQ) basis. This probably explains why the stock fell so much.\nWhere This Leaves BlackBerry\nLast year BlackBerry produced $893 million in revenue, but for this fiscal year ending May 2022 analysts still see lower sales at $781.6 million. However, they also expect a recovery by May 2023 to $954.1 million. But is the market willing to wait until then? That is why the upcoming fiscal Q2 2022 earnings release will be so important. Investors want to see if the company is back on a growth track.\nIf it is, then the likelihood that it can produce positive free cash flow for the year will increase, and this will help BB stock recover.\nFor example, as I pointed out in my last article, BlackBerry reported FCF during Q4 of $49 million. This was a huge 23.33% of its $210 million in revenue during the quarter. Assuming it can pull off the same thing next year the company could make $222.3 million in FCF that year. That is based on 23.33% of sales of $954.1 million.\nHowever, to be more conservative let’s assume that it can only make half of that or an 11.5% FCF margin. That lowers its forecast FCF to $109.7 million. Moreover, its present value using a 10% discount rate and a year and a half in the future is 86.68% times this FCF number. That lowers it to $95.1 million.\nWhat BlackBerry Stock Could Be Worth\nIf we use an FCF yield of between 1% we can calculate the company’s ongoing value. This is calculated by dividing the free cash flow estimates by its FCF yield ratio.\nFor example, using $95.1 million in FCF forecast for Blackberry in 2023 brings its value to $9.51 billion. This is 55.7% over today’s market value for Blackberry of $6.109 billion.\nAnd if we use a 1.5% FCF yield, the target market value falls to $6.34 billion (i.e., $95.1/0.015=$6.34b). That is just 3.78% over today’s price.\nTherefore, BB stock has a target value between 3.78% and 55.7% over today’s price. The average is 29.74%, or basically 30% over today’s price of $10.73. That puts its value at $13.95 per share (estimate rounded to $14).\nWhat to do With BB Stock\nAnalysts are not very positive about BB stock. For example, seven analysts surveyed by Refinitiv (reported by Yahoo! Finance) have an average target price of $8.36. That implies a potential drop of 22% from today’s price.\nAnother survey by TipRanks.com says that four analysts have an average price of $9.50or 11.5% below today’s price. However, nine Wall Street analysts surveyed by Seeking Alpha have an average target of $8.19, or 23.7% below today.\nSo the average of all three of these surveys is a price of $8.68, or 19% lower. I would not be too bothered by this though. Analysts have a tendency to raise their price targets after the stock has already risen.\nEnterprising investors who are willing to anticipate more positive results for the year ending May 2023 (and probably before that) could see the stock rise 30% to $13.95 per share.","news_type":1},"isVote":1,"tweetType":1,"viewCount":265,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":880231506,"gmtCreate":1631059158805,"gmtModify":1632884945504,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"Please like","listText":"Please like","text":"Please like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/880231506","repostId":"1180677223","repostType":4,"repost":{"id":"1180677223","kind":"news","pubTimestamp":1631057155,"share":"https://www.laohu8.com/m/news/1180677223?lang=&edition=full","pubTime":"2021-09-08 07:25","market":"us","language":"en","title":"Apple to Hold Sept. 14 Event for New iPhone Line, Other Devices","url":"https://stock-news.laohu8.com/highlight/detail?id=1180677223","media":"Bloomberg","summary":"Updated phones will feature smaller notch and improved cameras\nCompany to hold virtual event to show","content":"<ul>\n <li>Updated phones will feature smaller notch and improved cameras</li>\n <li>Company to hold virtual event to showcase latest hardware</li>\n</ul>\n<p>Apple Inc.&nbsp;has set the date for its biggest product launch of the year: Sept. 14. That’s when the company is set to unveil its latest line of iPhones and other products ahead of a critical holiday season.</p>\n<p>The presentation, which features the tag line “California streaming,” will take place at 10 a.m. Pacific time next Tuesday. Like all of Apple’s launches since 2020, the event will be held virtually due to the Covid-19 pandemic.</p>\n<p><img src=\"https://static.tigerbbs.com/41066bfafdd6b682c4449e5c0cbbdac0\" tg-width=\"883\" tg-height=\"833\" width=\"100%\" height=\"auto\"></p>\n<p>The Cupertino, California-based technology giant has been readying four new iPhones, as well as Apple Watches with larger screens,Bloomberg has reported. Apple has also been working on revamped entry-level AirPods earbuds and new MacBook Pros. Apple typically holds multiple launches in the fall, so not every new device for 2021 may appear next week. Last year, it held three events across two months.</p>\n<p>The fall product season is critical for Apple, with analysts estimating that the company will generate $120 billion in revenue during the holiday quarter. That would be an all-time record.</p>\n<p>The new iPhones are expected to have the same 5.4-inch, 6.1-inch and 6.7-inch screen sizes as last year’s iPhone 12, but the devices will include camera upgrades like a video version of Portrait mode, support for the higher-quality ProRes video recording resolution and more advanced filters system. Also coming to this year’s models are faster A15 processors, a smaller cutout at the top of the screen and display improvements like a faster refresh rate.</p>\n<p>Apple has also been planning a slew of satellite features for emergencies, such as a mechanism for reaching first-responder services and texting key contacts. While the new iPhone hardware may support the features, they aren’t expected to become available until sometime next year.</p>\n<p>The&nbsp;new Apple Watches&nbsp;will feature the first redesign to the product since the Series 4 in 2018. The new models will have flatter edges and displays, in addition to a&nbsp;sizable increase to the screen sizes. They’ll feature 41-millimeter and 45-millimeter cases, up from 40 and 44 millimeters.</p>\n<p>The larger model will also have a screen of about 1.9 inches diagonally, up from 1.78 inches. And it will include a faster processor and updated wireless technology. But the watches have faced production snags, which&nbsp;could result in shortages.</p>\n<p>Also coming this fall are the new MacBook Pros, iPads and AirPods. The MacBook Pros will be Apple’s first high-end computers to transition over to custom processors. And they’ll mark the first redesign to the MacBook Pro since 2016. The new models will include flatter edges and the removal of the Touch Bar strip on the keyboard. They also will offer MagSafe magnetic charging.</p>\n<p>The&nbsp;new AirPods will look similar&nbsp;to the AirPods Pro, but lack pricier features like noise cancellation. Apple hasn’t refreshed the entry-level earbuds since early 2019, but it released AirPods Max headphones last December.</p>\n<p>The company is&nbsp;planning two new iPads&nbsp;for this fall. First, an update to the base iPad geared toward schools. That version will get a faster processor and a thinner design. Second is the biggest overhaul to the iPad mini since the product first debuted in 2012. The new version will have a larger screen and thinner borders.</p>\n<p>Alongside the new hardware, Apple will also roll out the previously announced iOS and iPadOS 15, watchOS 8, tvOS 15 and macOS Monterey software updates. Apple typically gives release timing for those updates at these types of product launches.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple to Hold Sept. 14 Event for New iPhone Line, Other Devices</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple to Hold Sept. 14 Event for New iPhone Line, Other Devices\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-08 07:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-09-07/apple-to-hold-sept-14-event-for-new-iphone-line-other-devices><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Updated phones will feature smaller notch and improved cameras\nCompany to hold virtual event to showcase latest hardware\n\nApple Inc. has set the date for its biggest product launch of the year: Sept. ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-09-07/apple-to-hold-sept-14-event-for-new-iphone-line-other-devices\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.bloomberg.com/news/articles/2021-09-07/apple-to-hold-sept-14-event-for-new-iphone-line-other-devices","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1180677223","content_text":"Updated phones will feature smaller notch and improved cameras\nCompany to hold virtual event to showcase latest hardware\n\nApple Inc. has set the date for its biggest product launch of the year: Sept. 14. That’s when the company is set to unveil its latest line of iPhones and other products ahead of a critical holiday season.\nThe presentation, which features the tag line “California streaming,” will take place at 10 a.m. Pacific time next Tuesday. Like all of Apple’s launches since 2020, the event will be held virtually due to the Covid-19 pandemic.\n\nThe Cupertino, California-based technology giant has been readying four new iPhones, as well as Apple Watches with larger screens,Bloomberg has reported. Apple has also been working on revamped entry-level AirPods earbuds and new MacBook Pros. Apple typically holds multiple launches in the fall, so not every new device for 2021 may appear next week. Last year, it held three events across two months.\nThe fall product season is critical for Apple, with analysts estimating that the company will generate $120 billion in revenue during the holiday quarter. That would be an all-time record.\nThe new iPhones are expected to have the same 5.4-inch, 6.1-inch and 6.7-inch screen sizes as last year’s iPhone 12, but the devices will include camera upgrades like a video version of Portrait mode, support for the higher-quality ProRes video recording resolution and more advanced filters system. Also coming to this year’s models are faster A15 processors, a smaller cutout at the top of the screen and display improvements like a faster refresh rate.\nApple has also been planning a slew of satellite features for emergencies, such as a mechanism for reaching first-responder services and texting key contacts. While the new iPhone hardware may support the features, they aren’t expected to become available until sometime next year.\nThe new Apple Watches will feature the first redesign to the product since the Series 4 in 2018. The new models will have flatter edges and displays, in addition to a sizable increase to the screen sizes. They’ll feature 41-millimeter and 45-millimeter cases, up from 40 and 44 millimeters.\nThe larger model will also have a screen of about 1.9 inches diagonally, up from 1.78 inches. And it will include a faster processor and updated wireless technology. But the watches have faced production snags, which could result in shortages.\nAlso coming this fall are the new MacBook Pros, iPads and AirPods. The MacBook Pros will be Apple’s first high-end computers to transition over to custom processors. And they’ll mark the first redesign to the MacBook Pro since 2016. The new models will include flatter edges and the removal of the Touch Bar strip on the keyboard. They also will offer MagSafe magnetic charging.\nThe new AirPods will look similar to the AirPods Pro, but lack pricier features like noise cancellation. Apple hasn’t refreshed the entry-level earbuds since early 2019, but it released AirPods Max headphones last December.\nThe company is planning two new iPads for this fall. First, an update to the base iPad geared toward schools. That version will get a faster processor and a thinner design. Second is the biggest overhaul to the iPad mini since the product first debuted in 2012. The new version will have a larger screen and thinner borders.\nAlongside the new hardware, Apple will also roll out the previously announced iOS and iPadOS 15, watchOS 8, tvOS 15 and macOS Monterey software updates. Apple typically gives release timing for those updates at these types of product launches.","news_type":1},"isVote":1,"tweetType":1,"viewCount":56,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":814874109,"gmtCreate":1630809226401,"gmtModify":1631883609516,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BABA\">$Alibaba(BABA)$</a>Buy buy buy","listText":"<a href=\"https://laohu8.com/S/BABA\">$Alibaba(BABA)$</a>Buy buy buy","text":"$Alibaba(BABA)$Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/814874109","isVote":1,"tweetType":1,"viewCount":50,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":815410620,"gmtCreate":1630712371460,"gmtModify":1632466403884,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/815410620","repostId":"1107645720","repostType":4,"repost":{"id":"1107645720","kind":"news","pubTimestamp":1630679339,"share":"https://www.laohu8.com/m/news/1107645720?lang=&edition=full","pubTime":"2021-09-03 22:28","market":"us","language":"en","title":"After criticism, Apple says it will delay child safety updates","url":"https://stock-news.laohu8.com/highlight/detail?id=1107645720","media":"Reuters","summary":"Sept 3 (Reuters) - Apple Inc said on Friday it would take more time to collect feedback and improve ","content":"<p>Sept 3 (Reuters) - Apple Inc said on Friday it would take more time to collect feedback and improve proposed child safety features after the criticism of the system on privacy and other grounds both inside and outside the company.</p>\n<p>Apple's promise last month to check U.S. customer phones and computers for child sex abuse images sparked a global backlash from a wide range of rights groups, with employees also criticizing the plan internally.</p>\n<p>Critics argued the feature could be exploited by repressive governments looking to find other material for censorship or arrests and would also be impossible for outside researchers to determine whether Apple was only checking a small set of on-device content.</p>\n<p>Apple countered that it would allow security researchers to verify its claims, but the company on Friday said it would take more time to make changes to the system.</p>\n<p>\"Based on feedback from customers, advocacy groups, researchers and others, we have decided to take additional time over the coming months to collect input and make improvements before releasing these critically important child safety features,\" the company said in a statement on Friday.</p>\n<p>Matthew Green, a cybersecurity researcher at Johns Hopkins University who had criticized Apple's move, said the Apple's move was \"promising.\"</p>\n<p>Green said on Twitter that Apple should \"be clear about why you’re scanning and what you’re scanning. Going from scanning nothing (but email attachments) to scanning everyone’s private photo library was an enormous delta. You need to justify escalations like this.\"</p>\n<p>Apple had been playing defense on the plan for weeks, and had already offered a series of explanations and documents to show that the risks of false detections were low.</p>\n<p>It had planned to roll out the feature for iPhones, iPads, and Mac with software updates later this year in the United States.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After criticism, Apple says it will delay child safety updates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter criticism, Apple says it will delay child safety updates\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-03 22:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/2-apple-says-delays-child-132336835.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sept 3 (Reuters) - Apple Inc said on Friday it would take more time to collect feedback and improve proposed child safety features after the criticism of the system on privacy and other grounds both ...</p>\n\n<a href=\"https://finance.yahoo.com/news/2-apple-says-delays-child-132336835.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://finance.yahoo.com/news/2-apple-says-delays-child-132336835.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1107645720","content_text":"Sept 3 (Reuters) - Apple Inc said on Friday it would take more time to collect feedback and improve proposed child safety features after the criticism of the system on privacy and other grounds both inside and outside the company.\nApple's promise last month to check U.S. customer phones and computers for child sex abuse images sparked a global backlash from a wide range of rights groups, with employees also criticizing the plan internally.\nCritics argued the feature could be exploited by repressive governments looking to find other material for censorship or arrests and would also be impossible for outside researchers to determine whether Apple was only checking a small set of on-device content.\nApple countered that it would allow security researchers to verify its claims, but the company on Friday said it would take more time to make changes to the system.\n\"Based on feedback from customers, advocacy groups, researchers and others, we have decided to take additional time over the coming months to collect input and make improvements before releasing these critically important child safety features,\" the company said in a statement on Friday.\nMatthew Green, a cybersecurity researcher at Johns Hopkins University who had criticized Apple's move, said the Apple's move was \"promising.\"\nGreen said on Twitter that Apple should \"be clear about why you’re scanning and what you’re scanning. Going from scanning nothing (but email attachments) to scanning everyone’s private photo library was an enormous delta. You need to justify escalations like this.\"\nApple had been playing defense on the plan for weeks, and had already offered a series of explanations and documents to show that the risks of false detections were low.\nIt had planned to roll out the feature for iPhones, iPads, and Mac with software updates later this year in the United States.","news_type":1},"isVote":1,"tweetType":1,"viewCount":35,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":812794555,"gmtCreate":1630623442677,"gmtModify":1632470284615,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"Like please","listText":"Like please","text":"Like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/812794555","repostId":"2164984716","repostType":4,"isVote":1,"tweetType":1,"viewCount":80,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":812647240,"gmtCreate":1630587410680,"gmtModify":1632471695295,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/812647240","repostId":"2164844008","repostType":4,"isVote":1,"tweetType":1,"viewCount":56,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":813597160,"gmtCreate":1630211287050,"gmtModify":1704957106811,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"Please like","listText":"Please like","text":"Please like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/813597160","repostId":"1162964424","repostType":4,"isVote":1,"tweetType":1,"viewCount":93,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":819869957,"gmtCreate":1630055085479,"gmtModify":1704955259393,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"Please like","listText":"Please like","text":"Please like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/819869957","repostId":"1158698371","repostType":4,"isVote":1,"tweetType":1,"viewCount":114,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":873062154,"gmtCreate":1636803354904,"gmtModify":1636803355129,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"Just sold mine&nbsp;","listText":"Just sold mine&nbsp;","text":"Just sold mine","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/873062154","repostId":"1102251183","repostType":2,"repost":{"id":"1102251183","kind":"news","pubTimestamp":1636772424,"share":"https://www.laohu8.com/m/news/1102251183?lang=&edition=full","pubTime":"2021-11-13 11:00","market":"us","language":"en","title":"Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.","url":"https://stock-news.laohu8.com/highlight/detail?id=1102251183","media":"Barrons","summary":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo","content":"<p>Pfizer’s&nbsp;chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p>\n<p>“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p>\n<p>Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p>\n<p>Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p>\n<p>In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p>\n<p>The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p>\n<p>Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like&nbsp;Johnson &amp; Johnson&nbsp;(JNJ) and&nbsp;Eli Lilly&nbsp;(LLY).</p>\n<p>The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p>\n<p>The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p>\n<p>The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p>\n<p>While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech&nbsp;BioNTech&nbsp;(BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p>\n<p>In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p>\n<p>The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p>\n<p>“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p>\n<p>Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p>\n<p>“[Pfizer’s] pharmaceutical R&amp;D is better than people had thought.”</p>\n<p>The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p>\n<p>“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p>\n<p>Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from&nbsp;Merck&nbsp;(MRK).</p>\n<p>“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&amp;D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p>\n<p>Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p>\n<p>“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p>\n<p>That makes a bet on Pfizer a long-term play. In the meantime, the experience of&nbsp;Moderna&nbsp;(MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p>\n<p>Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p>\n<p>Moderna shares are down more than 40% over the past three months.</p>\n<p>As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p>\n<p>When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p>\n<p>That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p>\n<p>Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p>\n<p>Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p>\n<p>An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-13 11:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that...</p>\n\n<a href=\"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102251183","content_text":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.\n“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.\nTwo years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.\nBourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.\nIn a cover story in November 2019, Barron’s argued that Bourla and Dolsten could pull it off.\nThe new antiviral data reaffirms the case for Pfizer that Barron’s made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.\nPfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).\nThe Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.\nThe worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.\nThe success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.\nWhile Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.\nIn the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.\nThe antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.\n“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.\nDolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.\n“[Pfizer’s] pharmaceutical R&D is better than people had thought.”\nThe protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.\n“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.\nPfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).\n“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.\nChen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.\n“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”\nThat makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.\nBiden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”\nModerna shares are down more than 40% over the past three months.\nAs the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling Barron’s that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.\nWhen it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.\nThat contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.\nDolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”\nSuch a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.\nAn aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.","news_type":1},"isVote":1,"tweetType":1,"viewCount":676,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":848406158,"gmtCreate":1636016403992,"gmtModify":1636016404375,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"Dun drop please","listText":"Dun drop please","text":"Dun drop please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/848406158","repostId":"1167064150","repostType":4,"repost":{"id":"1167064150","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636015649,"share":"https://www.laohu8.com/m/news/1167064150?lang=&edition=full","pubTime":"2021-11-04 16:47","market":"us","language":"en","title":"Hot chinese concept stocks rallied in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1167064150","media":"Tiger Newspress","summary":"Hot chinese concept stocks rallied in premarket trading.Alibaba,JD.com,Pinduoduo,Baidu,Bilibili,KE h","content":"<p>Hot&nbsp;chinese&nbsp;concept&nbsp;stocks&nbsp;rallied&nbsp;in&nbsp;premarket&nbsp;trading.Alibaba,JD.com,Pinduoduo,Baidu,Bilibili,KE holding,Didi Global,Nio,Xpeng Motors and Li Auto climbed between 1% and 4%.</p>\n<p><img src=\"https://static.tigerbbs.com/62b8b12c5eeaa21666c060337f5740ff\" tg-width=\"403\" tg-height=\"718\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hot chinese concept stocks rallied in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHot chinese concept stocks rallied in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-04 16:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hot&nbsp;chinese&nbsp;concept&nbsp;stocks&nbsp;rallied&nbsp;in&nbsp;premarket&nbsp;trading.Alibaba,JD.com,Pinduoduo,Baidu,Bilibili,KE holding,Didi Global,Nio,Xpeng Motors and Li Auto climbed between 1% and 4%.</p>\n<p><img src=\"https://static.tigerbbs.com/62b8b12c5eeaa21666c060337f5740ff\" tg-width=\"403\" tg-height=\"718\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JD":"京东","PDD":"拼多多","BABA":"阿里巴巴"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167064150","content_text":"Hot chinese concept stocks rallied in premarket trading.Alibaba,JD.com,Pinduoduo,Baidu,Bilibili,KE holding,Didi Global,Nio,Xpeng Motors and Li Auto climbed between 1% and 4%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":748,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":888878331,"gmtCreate":1631490837623,"gmtModify":1632810232026,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"Like please","listText":"Like please","text":"Like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/888878331","repostId":"1101906502","repostType":4,"repost":{"id":"1101906502","kind":"news","pubTimestamp":1631407634,"share":"https://www.laohu8.com/m/news/1101906502?lang=&edition=full","pubTime":"2021-09-12 08:47","market":"us","language":"en","title":"Buy or Sell Apple Stock Ahead of iPhone Event?","url":"https://stock-news.laohu8.com/highlight/detail?id=1101906502","media":"TheStreet","summary":"Apple stock was under pressure on Friday, with its iPhone event just days away. Here's how to trade the stock from here.Shares of Apple Report fell $5.10, or 3.31%, to end at $148.97 Friday, as investors digested recent news and prepared for the iPhone event next week.On Sept. 14, the company will hold a virtual event to introduce the new device. Dubbed “California Streaming,” it’s expected that Apple will introduce its new iPhone and Apple Watch.However, Apple remains in the news for other reas","content":"<p>Apple stock was under pressure on Friday, with its iPhone event just days away. Here's how to trade the stock from here.</p>\n<p>Shares of Apple&nbsp;Report&nbsp;fell $5.10, or 3.31%, to end at $148.97 Friday, as investors digested recent news and prepared for the iPhone event next week.</p>\n<p>On Sept. 14, the company will&nbsp;hold a virtual event to introduce&nbsp;the new device. Dubbed “California Streaming,” it’s expected that Apple will introduce its new iPhone and Apple Watch.</p>\n<p>However, Apple remains in the news for other reasons, too.</p>\n<p>After hitting new highs earlier this week, the stock declined Friday after news of a court ruling&nbsp;in its case with Epic Games.</p>\n<p>That’s alongside a report that was published by well-known Morgan Stanley analyst Katy Huberty, who made the case that Apple stock&nbsp;is “compelling” ahead of its upcoming event.</p>\n<p>Like I said, it’s a lot of information for investors to digest. Let’s take a look at how the charts are setting up.</p>\n<p><b>Trading Apple Stock</b></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/bd94f6dcfc32af44a4ae542425f3c92f\" tg-width=\"700\" tg-height=\"429\" width=\"100%\" height=\"auto\"><span>Daily chart of Apple stock.</span></p>\n<p>Each time Apple has reported earnings this year, it has resulted in a selloff. Unfortunately, those selloffs would come right as the stock was at or near all-time highs. Those events are marked on the chart with blue arrows.</p>\n<p>It was even more frustrating that Apple&nbsp;blew out analysts’ expectations each time, yet the stock sold off anyway.</p>\n<p>However, rather than a massive dip following the most recent report, the stock only pulled back to the $145 area, near the prior high. It also held the 21-day moving average as support.</p>\n<p>The stock has since pushed up through $150 and earlier this week, hit new all-time highs.</p>\n<p>For now, we’re getting a dip back down to the key $150 area and the 21-day moving average. Aggressive bulls can buy this dip ahead of the company’s event on Tuesday.</p>\n<p>If we break Friday’s low, investors may consider stopping out of the trade and buying on a potentially larger dip down to the 50-day moving average or the $145 area.</p>\n<p>Below $145 may put the $138 level and the 200-day moving average in play.</p>\n<p>Should Apple trade up through the all-time high at $157.26, the 161.8% extension is in play up near $160. Above that mark could put the $172 to $175 zone on the table, depending on how investors react to the event.</p>\n<p>For what it’s worth, September is by far Apple’s worst-performing month, up just three of the last 11 years for the month.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Buy or Sell Apple Stock Ahead of iPhone Event?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBuy or Sell Apple Stock Ahead of iPhone Event?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-12 08:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/trading-apple-aapl-stock-ahead-of-iphone13-event><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Apple stock was under pressure on Friday, with its iPhone event just days away. Here's how to trade the stock from here.\nShares of Apple Report fell $5.10, or 3.31%, to end at $148.97 Friday, as ...</p>\n\n<a href=\"https://www.thestreet.com/investing/trading-apple-aapl-stock-ahead-of-iphone13-event\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.thestreet.com/investing/trading-apple-aapl-stock-ahead-of-iphone13-event","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101906502","content_text":"Apple stock was under pressure on Friday, with its iPhone event just days away. Here's how to trade the stock from here.\nShares of Apple Report fell $5.10, or 3.31%, to end at $148.97 Friday, as investors digested recent news and prepared for the iPhone event next week.\nOn Sept. 14, the company will hold a virtual event to introduce the new device. Dubbed “California Streaming,” it’s expected that Apple will introduce its new iPhone and Apple Watch.\nHowever, Apple remains in the news for other reasons, too.\nAfter hitting new highs earlier this week, the stock declined Friday after news of a court ruling in its case with Epic Games.\nThat’s alongside a report that was published by well-known Morgan Stanley analyst Katy Huberty, who made the case that Apple stock is “compelling” ahead of its upcoming event.\nLike I said, it’s a lot of information for investors to digest. Let’s take a look at how the charts are setting up.\nTrading Apple Stock\nDaily chart of Apple stock.\nEach time Apple has reported earnings this year, it has resulted in a selloff. Unfortunately, those selloffs would come right as the stock was at or near all-time highs. Those events are marked on the chart with blue arrows.\nIt was even more frustrating that Apple blew out analysts’ expectations each time, yet the stock sold off anyway.\nHowever, rather than a massive dip following the most recent report, the stock only pulled back to the $145 area, near the prior high. It also held the 21-day moving average as support.\nThe stock has since pushed up through $150 and earlier this week, hit new all-time highs.\nFor now, we’re getting a dip back down to the key $150 area and the 21-day moving average. Aggressive bulls can buy this dip ahead of the company’s event on Tuesday.\nIf we break Friday’s low, investors may consider stopping out of the trade and buying on a potentially larger dip down to the 50-day moving average or the $145 area.\nBelow $145 may put the $138 level and the 200-day moving average in play.\nShould Apple trade up through the all-time high at $157.26, the 161.8% extension is in play up near $160. Above that mark could put the $172 to $175 zone on the table, depending on how investors react to the event.\nFor what it’s worth, September is by far Apple’s worst-performing month, up just three of the last 11 years for the month.","news_type":1},"isVote":1,"tweetType":1,"viewCount":130,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":880231506,"gmtCreate":1631059158805,"gmtModify":1632884945504,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"Please like","listText":"Please like","text":"Please like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/880231506","repostId":"1180677223","repostType":4,"repost":{"id":"1180677223","kind":"news","pubTimestamp":1631057155,"share":"https://www.laohu8.com/m/news/1180677223?lang=&edition=full","pubTime":"2021-09-08 07:25","market":"us","language":"en","title":"Apple to Hold Sept. 14 Event for New iPhone Line, Other Devices","url":"https://stock-news.laohu8.com/highlight/detail?id=1180677223","media":"Bloomberg","summary":"Updated phones will feature smaller notch and improved cameras\nCompany to hold virtual event to show","content":"<ul>\n <li>Updated phones will feature smaller notch and improved cameras</li>\n <li>Company to hold virtual event to showcase latest hardware</li>\n</ul>\n<p>Apple Inc.&nbsp;has set the date for its biggest product launch of the year: Sept. 14. That’s when the company is set to unveil its latest line of iPhones and other products ahead of a critical holiday season.</p>\n<p>The presentation, which features the tag line “California streaming,” will take place at 10 a.m. Pacific time next Tuesday. Like all of Apple’s launches since 2020, the event will be held virtually due to the Covid-19 pandemic.</p>\n<p><img src=\"https://static.tigerbbs.com/41066bfafdd6b682c4449e5c0cbbdac0\" tg-width=\"883\" tg-height=\"833\" width=\"100%\" height=\"auto\"></p>\n<p>The Cupertino, California-based technology giant has been readying four new iPhones, as well as Apple Watches with larger screens,Bloomberg has reported. Apple has also been working on revamped entry-level AirPods earbuds and new MacBook Pros. Apple typically holds multiple launches in the fall, so not every new device for 2021 may appear next week. Last year, it held three events across two months.</p>\n<p>The fall product season is critical for Apple, with analysts estimating that the company will generate $120 billion in revenue during the holiday quarter. That would be an all-time record.</p>\n<p>The new iPhones are expected to have the same 5.4-inch, 6.1-inch and 6.7-inch screen sizes as last year’s iPhone 12, but the devices will include camera upgrades like a video version of Portrait mode, support for the higher-quality ProRes video recording resolution and more advanced filters system. Also coming to this year’s models are faster A15 processors, a smaller cutout at the top of the screen and display improvements like a faster refresh rate.</p>\n<p>Apple has also been planning a slew of satellite features for emergencies, such as a mechanism for reaching first-responder services and texting key contacts. While the new iPhone hardware may support the features, they aren’t expected to become available until sometime next year.</p>\n<p>The&nbsp;new Apple Watches&nbsp;will feature the first redesign to the product since the Series 4 in 2018. The new models will have flatter edges and displays, in addition to a&nbsp;sizable increase to the screen sizes. They’ll feature 41-millimeter and 45-millimeter cases, up from 40 and 44 millimeters.</p>\n<p>The larger model will also have a screen of about 1.9 inches diagonally, up from 1.78 inches. And it will include a faster processor and updated wireless technology. But the watches have faced production snags, which&nbsp;could result in shortages.</p>\n<p>Also coming this fall are the new MacBook Pros, iPads and AirPods. The MacBook Pros will be Apple’s first high-end computers to transition over to custom processors. And they’ll mark the first redesign to the MacBook Pro since 2016. The new models will include flatter edges and the removal of the Touch Bar strip on the keyboard. They also will offer MagSafe magnetic charging.</p>\n<p>The&nbsp;new AirPods will look similar&nbsp;to the AirPods Pro, but lack pricier features like noise cancellation. Apple hasn’t refreshed the entry-level earbuds since early 2019, but it released AirPods Max headphones last December.</p>\n<p>The company is&nbsp;planning two new iPads&nbsp;for this fall. First, an update to the base iPad geared toward schools. That version will get a faster processor and a thinner design. Second is the biggest overhaul to the iPad mini since the product first debuted in 2012. The new version will have a larger screen and thinner borders.</p>\n<p>Alongside the new hardware, Apple will also roll out the previously announced iOS and iPadOS 15, watchOS 8, tvOS 15 and macOS Monterey software updates. Apple typically gives release timing for those updates at these types of product launches.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple to Hold Sept. 14 Event for New iPhone Line, Other Devices</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple to Hold Sept. 14 Event for New iPhone Line, Other Devices\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-08 07:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-09-07/apple-to-hold-sept-14-event-for-new-iphone-line-other-devices><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Updated phones will feature smaller notch and improved cameras\nCompany to hold virtual event to showcase latest hardware\n\nApple Inc. has set the date for its biggest product launch of the year: Sept. ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-09-07/apple-to-hold-sept-14-event-for-new-iphone-line-other-devices\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.bloomberg.com/news/articles/2021-09-07/apple-to-hold-sept-14-event-for-new-iphone-line-other-devices","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1180677223","content_text":"Updated phones will feature smaller notch and improved cameras\nCompany to hold virtual event to showcase latest hardware\n\nApple Inc. has set the date for its biggest product launch of the year: Sept. 14. That’s when the company is set to unveil its latest line of iPhones and other products ahead of a critical holiday season.\nThe presentation, which features the tag line “California streaming,” will take place at 10 a.m. Pacific time next Tuesday. Like all of Apple’s launches since 2020, the event will be held virtually due to the Covid-19 pandemic.\n\nThe Cupertino, California-based technology giant has been readying four new iPhones, as well as Apple Watches with larger screens,Bloomberg has reported. Apple has also been working on revamped entry-level AirPods earbuds and new MacBook Pros. Apple typically holds multiple launches in the fall, so not every new device for 2021 may appear next week. Last year, it held three events across two months.\nThe fall product season is critical for Apple, with analysts estimating that the company will generate $120 billion in revenue during the holiday quarter. That would be an all-time record.\nThe new iPhones are expected to have the same 5.4-inch, 6.1-inch and 6.7-inch screen sizes as last year’s iPhone 12, but the devices will include camera upgrades like a video version of Portrait mode, support for the higher-quality ProRes video recording resolution and more advanced filters system. Also coming to this year’s models are faster A15 processors, a smaller cutout at the top of the screen and display improvements like a faster refresh rate.\nApple has also been planning a slew of satellite features for emergencies, such as a mechanism for reaching first-responder services and texting key contacts. While the new iPhone hardware may support the features, they aren’t expected to become available until sometime next year.\nThe new Apple Watches will feature the first redesign to the product since the Series 4 in 2018. The new models will have flatter edges and displays, in addition to a sizable increase to the screen sizes. They’ll feature 41-millimeter and 45-millimeter cases, up from 40 and 44 millimeters.\nThe larger model will also have a screen of about 1.9 inches diagonally, up from 1.78 inches. And it will include a faster processor and updated wireless technology. But the watches have faced production snags, which could result in shortages.\nAlso coming this fall are the new MacBook Pros, iPads and AirPods. The MacBook Pros will be Apple’s first high-end computers to transition over to custom processors. And they’ll mark the first redesign to the MacBook Pro since 2016. The new models will include flatter edges and the removal of the Touch Bar strip on the keyboard. They also will offer MagSafe magnetic charging.\nThe new AirPods will look similar to the AirPods Pro, but lack pricier features like noise cancellation. Apple hasn’t refreshed the entry-level earbuds since early 2019, but it released AirPods Max headphones last December.\nThe company is planning two new iPads for this fall. First, an update to the base iPad geared toward schools. That version will get a faster processor and a thinner design. Second is the biggest overhaul to the iPad mini since the product first debuted in 2012. The new version will have a larger screen and thinner borders.\nAlongside the new hardware, Apple will also roll out the previously announced iOS and iPadOS 15, watchOS 8, tvOS 15 and macOS Monterey software updates. Apple typically gives release timing for those updates at these types of product launches.","news_type":1},"isVote":1,"tweetType":1,"viewCount":56,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":174607165,"gmtCreate":1627093245357,"gmtModify":1633768046169,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/174607165","repostId":"2153980423","repostType":4,"repost":{"id":"2153980423","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1627081209,"share":"https://www.laohu8.com/m/news/2153980423?lang=&edition=full","pubTime":"2021-07-24 07:00","market":"us","language":"en","title":"Wall Street surges to all-time closing high on earnings, economic revival","url":"https://stock-news.laohu8.com/highlight/detail?id=2153980423","media":"Reuters","summary":"* All 3 major indexes post weekly gains\n* Dow closes above 35,000 for first time ever\n* Social media","content":"<p>* All 3 major indexes post weekly gains</p>\n<p>* Dow closes above 35,000 for first time ever</p>\n<p>* Social media stocks rally after upbeat results</p>\n<p>* Intel sales forecast implies rocky second half</p>\n<p>* Indexes up: Dow 0.68%, S&amp;P 1.01%, Nasdaq 1.04%</p>\n<p>Wall Street gained ground for the fourth straight session on Friday, extending a rally that pushed all three major U.S. stock indexes to record closing highs as upbeat earnings and signs of economic revival fueled investor risk appetite.</p>\n<p>The Dow closed above 35,000 for the first time ever.</p>\n<p>\"We see a continuation of the last couple days. It's roller coaster in reverse. We did the drop first, and we’ve been climbing back to the top ever since,\" said Chris Zaccarelli, chief investment officer at Independent Advisor Alliance in Charlotte, North Carolina.</p>\n<p>Growth and value stocks seesawed for much of the week as market participants weighed spiking infections of the COVID-19 Delta variant against strong corporate results and signs of economic revival.</p>\n<p>\"There’s push and pull, there’s clearly conflict in the market,\" Zaccarelli added. \"There’s a strong difference of opinion as to whether the future’s bright or whether there are clouds on the horizon.\"</p>\n<p>Market participants now look toward next week with the Federal Reserve's two-day monetary policy meeting and a series of high-profile earnings.</p>\n<p>The Fed's statement will be parsed for clues regarding the timeframe for tightening its accommodative policies, although Chairman Jerome Powell has repeatedly said the economy still needs the central bank's full support.</p>\n<p>The Dow Jones Industrial Average rose 238.2 points, or 0.68%, to 35,061.55, the S&amp;P 500 gained 44.31 points, or 1.01%, to 4,411.79 and the Nasdaq Composite added 152.39 points, or 1.04%, to 14,836.99.</p>\n<p>Of the 11 major sectors in the S&amp;P 500, all but energy&nbsp;closed green, with communications services enjoying the largest gain, rising 2.7%.</p>\n<p>Second-quarter reporting season is in full swing, with 120 of the companies in the S&amp;P 500 having reported. Of those, 88% have beaten consensus, according to Refinitiv.</p>\n<p>\"We’re seeing companies, on average, beat on the top and on the bottom line,\" Zaccarelli said. \"We’re seeing the resilience of the consumer and that’s been the story of the earnings season so far.\"</p>\n<p>Analysts now expect aggregate year-on-year S&amp;P 500 earnings growth of 78.1% for the April to June period, a sizeable increase from the 54% annual growth seen at the beginning of the quarter.</p>\n<p>Chipmaker Intel Corp said late Thursday that it still faces supply constraints and provided disappointing guidance. Its stock fell 5.3%.</p>\n<p>Moderna Inc jumped 7.8% after the European Union approved its COVID-19 vaccine for 12- to 17-year-olds.</p>\n<p>American <a href=\"https://laohu8.com/S/EXPR\">Express</a> Co gained 1.3% after posting second-quarter profit that handily beat expectations on the strength of a global recovery in consumer spending.</p>\n<p>Social media firms <a href=\"https://laohu8.com/S/TWTR\">Twitter</a> Inc and <a href=\"https://laohu8.com/S/SNAP\">Snap Inc</a>&nbsp;advanced 3.0% and 23.8%, respectively, on the back of their upbeat results.</p>\n<p>Those results bode well for <a href=\"https://laohu8.com/S/FB\">Facebook</a> Inc, which is due to post second-quarter results next week. Its stock surged 5.3%.</p>\n<p>Other high-profile earnings expected next week include Tesla Inc, Apple Inc, Alphabet Inc, Microsoft Corp and Amazon.com.</p>\n<p>Industrials Lockheed Martin Corp, Boeing Co, Ford Motor Co, General Dynamics Corp, <a href=\"https://laohu8.com/S/MMM\">3M</a> Co Caterpillar Inc, Chevron Corp and Exxon Mobil Corp, along with a host of healthcare, consumer goods and others, are also on deck.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 1.59-to-1 ratio; on Nasdaq, a 1.03-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 82 new 52-week highs and no new lows; the Nasdaq Composite recorded 81 new highs and 136 new lows.</p>\n<p>Volume on U.S. exchanges was 9.72 billion shares, compared with the 10.14 billion average over the last 20 trading days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street surges to all-time closing high on earnings, economic revival</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street surges to all-time closing high on earnings, economic revival\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-24 07:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>* All 3 major indexes post weekly gains</p>\n<p>* Dow closes above 35,000 for first time ever</p>\n<p>* Social media stocks rally after upbeat results</p>\n<p>* Intel sales forecast implies rocky second half</p>\n<p>* Indexes up: Dow 0.68%, S&amp;P 1.01%, Nasdaq 1.04%</p>\n<p>Wall Street gained ground for the fourth straight session on Friday, extending a rally that pushed all three major U.S. stock indexes to record closing highs as upbeat earnings and signs of economic revival fueled investor risk appetite.</p>\n<p>The Dow closed above 35,000 for the first time ever.</p>\n<p>\"We see a continuation of the last couple days. It's roller coaster in reverse. We did the drop first, and we’ve been climbing back to the top ever since,\" said Chris Zaccarelli, chief investment officer at Independent Advisor Alliance in Charlotte, North Carolina.</p>\n<p>Growth and value stocks seesawed for much of the week as market participants weighed spiking infections of the COVID-19 Delta variant against strong corporate results and signs of economic revival.</p>\n<p>\"There’s push and pull, there’s clearly conflict in the market,\" Zaccarelli added. \"There’s a strong difference of opinion as to whether the future’s bright or whether there are clouds on the horizon.\"</p>\n<p>Market participants now look toward next week with the Federal Reserve's two-day monetary policy meeting and a series of high-profile earnings.</p>\n<p>The Fed's statement will be parsed for clues regarding the timeframe for tightening its accommodative policies, although Chairman Jerome Powell has repeatedly said the economy still needs the central bank's full support.</p>\n<p>The Dow Jones Industrial Average rose 238.2 points, or 0.68%, to 35,061.55, the S&amp;P 500 gained 44.31 points, or 1.01%, to 4,411.79 and the Nasdaq Composite added 152.39 points, or 1.04%, to 14,836.99.</p>\n<p>Of the 11 major sectors in the S&amp;P 500, all but energy&nbsp;closed green, with communications services enjoying the largest gain, rising 2.7%.</p>\n<p>Second-quarter reporting season is in full swing, with 120 of the companies in the S&amp;P 500 having reported. Of those, 88% have beaten consensus, according to Refinitiv.</p>\n<p>\"We’re seeing companies, on average, beat on the top and on the bottom line,\" Zaccarelli said. \"We’re seeing the resilience of the consumer and that’s been the story of the earnings season so far.\"</p>\n<p>Analysts now expect aggregate year-on-year S&amp;P 500 earnings growth of 78.1% for the April to June period, a sizeable increase from the 54% annual growth seen at the beginning of the quarter.</p>\n<p>Chipmaker Intel Corp said late Thursday that it still faces supply constraints and provided disappointing guidance. Its stock fell 5.3%.</p>\n<p>Moderna Inc jumped 7.8% after the European Union approved its COVID-19 vaccine for 12- to 17-year-olds.</p>\n<p>American <a href=\"https://laohu8.com/S/EXPR\">Express</a> Co gained 1.3% after posting second-quarter profit that handily beat expectations on the strength of a global recovery in consumer spending.</p>\n<p>Social media firms <a href=\"https://laohu8.com/S/TWTR\">Twitter</a> Inc and <a href=\"https://laohu8.com/S/SNAP\">Snap Inc</a>&nbsp;advanced 3.0% and 23.8%, respectively, on the back of their upbeat results.</p>\n<p>Those results bode well for <a href=\"https://laohu8.com/S/FB\">Facebook</a> Inc, which is due to post second-quarter results next week. Its stock surged 5.3%.</p>\n<p>Other high-profile earnings expected next week include Tesla Inc, Apple Inc, Alphabet Inc, Microsoft Corp and Amazon.com.</p>\n<p>Industrials Lockheed Martin Corp, Boeing Co, Ford Motor Co, General Dynamics Corp, <a href=\"https://laohu8.com/S/MMM\">3M</a> Co Caterpillar Inc, Chevron Corp and Exxon Mobil Corp, along with a host of healthcare, consumer goods and others, are also on deck.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 1.59-to-1 ratio; on Nasdaq, a 1.03-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 82 new 52-week highs and no new lows; the Nasdaq Composite recorded 81 new highs and 136 new lows.</p>\n<p>Volume on U.S. exchanges was 9.72 billion shares, compared with the 10.14 billion average over the last 20 trading days.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".IXIC":"NASDAQ Composite","SNAP":"Snap Inc","EXPR":"Express, Inc.",".SPX":"S&P 500 Index","TWTR":"Twitter"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153980423","content_text":"* All 3 major indexes post weekly gains\n* Dow closes above 35,000 for first time ever\n* Social media stocks rally after upbeat results\n* Intel sales forecast implies rocky second half\n* Indexes up: Dow 0.68%, S&P 1.01%, Nasdaq 1.04%\nWall Street gained ground for the fourth straight session on Friday, extending a rally that pushed all three major U.S. stock indexes to record closing highs as upbeat earnings and signs of economic revival fueled investor risk appetite.\nThe Dow closed above 35,000 for the first time ever.\n\"We see a continuation of the last couple days. It's roller coaster in reverse. We did the drop first, and we’ve been climbing back to the top ever since,\" said Chris Zaccarelli, chief investment officer at Independent Advisor Alliance in Charlotte, North Carolina.\nGrowth and value stocks seesawed for much of the week as market participants weighed spiking infections of the COVID-19 Delta variant against strong corporate results and signs of economic revival.\n\"There’s push and pull, there’s clearly conflict in the market,\" Zaccarelli added. \"There’s a strong difference of opinion as to whether the future’s bright or whether there are clouds on the horizon.\"\nMarket participants now look toward next week with the Federal Reserve's two-day monetary policy meeting and a series of high-profile earnings.\nThe Fed's statement will be parsed for clues regarding the timeframe for tightening its accommodative policies, although Chairman Jerome Powell has repeatedly said the economy still needs the central bank's full support.\nThe Dow Jones Industrial Average rose 238.2 points, or 0.68%, to 35,061.55, the S&P 500 gained 44.31 points, or 1.01%, to 4,411.79 and the Nasdaq Composite added 152.39 points, or 1.04%, to 14,836.99.\nOf the 11 major sectors in the S&P 500, all but energy closed green, with communications services enjoying the largest gain, rising 2.7%.\nSecond-quarter reporting season is in full swing, with 120 of the companies in the S&P 500 having reported. Of those, 88% have beaten consensus, according to Refinitiv.\n\"We’re seeing companies, on average, beat on the top and on the bottom line,\" Zaccarelli said. \"We’re seeing the resilience of the consumer and that’s been the story of the earnings season so far.\"\nAnalysts now expect aggregate year-on-year S&P 500 earnings growth of 78.1% for the April to June period, a sizeable increase from the 54% annual growth seen at the beginning of the quarter.\nChipmaker Intel Corp said late Thursday that it still faces supply constraints and provided disappointing guidance. Its stock fell 5.3%.\nModerna Inc jumped 7.8% after the European Union approved its COVID-19 vaccine for 12- to 17-year-olds.\nAmerican Express Co gained 1.3% after posting second-quarter profit that handily beat expectations on the strength of a global recovery in consumer spending.\nSocial media firms Twitter Inc and Snap Inc advanced 3.0% and 23.8%, respectively, on the back of their upbeat results.\nThose results bode well for Facebook Inc, which is due to post second-quarter results next week. Its stock surged 5.3%.\nOther high-profile earnings expected next week include Tesla Inc, Apple Inc, Alphabet Inc, Microsoft Corp and Amazon.com.\nIndustrials Lockheed Martin Corp, Boeing Co, Ford Motor Co, General Dynamics Corp, 3M Co Caterpillar Inc, Chevron Corp and Exxon Mobil Corp, along with a host of healthcare, consumer goods and others, are also on deck.\nAdvancing issues outnumbered declining ones on the NYSE by a 1.59-to-1 ratio; on Nasdaq, a 1.03-to-1 ratio favored advancers.\nThe S&P 500 posted 82 new 52-week highs and no new lows; the Nasdaq Composite recorded 81 new highs and 136 new lows.\nVolume on U.S. exchanges was 9.72 billion shares, compared with the 10.14 billion average over the last 20 trading days.","news_type":1},"isVote":1,"tweetType":1,"viewCount":118,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":171566250,"gmtCreate":1626751027670,"gmtModify":1633771376067,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/171566250","repostId":"2152652683","repostType":4,"isVote":1,"tweetType":1,"viewCount":70,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":145647280,"gmtCreate":1626223248840,"gmtModify":1633928924252,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/145647280","repostId":"1129021416","repostType":4,"isVote":1,"tweetType":1,"viewCount":29,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":142793618,"gmtCreate":1626174380234,"gmtModify":1633929416770,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BABA\">$Alibaba(BABA)$</a>can buy now?","listText":"<a href=\"https://laohu8.com/S/BABA\">$Alibaba(BABA)$</a>can buy now?","text":"$Alibaba(BABA)$can buy now?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/142793618","isVote":1,"tweetType":1,"viewCount":812,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":152827786,"gmtCreate":1625282468245,"gmtModify":1633941769892,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"What's next?","listText":"What's next?","text":"What's next?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/152827786","repostId":"1114445293","repostType":4,"repost":{"id":"1114445293","kind":"news","pubTimestamp":1625277820,"share":"https://www.laohu8.com/m/news/1114445293?lang=&edition=full","pubTime":"2021-07-03 10:03","market":"us","language":"en","title":"Robinhood’s IPO Could Be a Sign the Stock Market Has Peaked","url":"https://stock-news.laohu8.com/highlight/detail?id=1114445293","media":"Barron's","summary":"Nothing succeeds like excess, as the old quip goes. Until it doesn’t, which has been the distinguish","content":"<p>Nothing succeeds like excess, as the old quip goes. Until it doesn’t, which has been the distinguishing aspect of market cycles forever and, most dramatically, in this century. Unlike last year’s pandemic-induced paroxysm, the 2000 bursting of the dot-com bubble and the 2008 financial crisis were marked by initial public offerings by companies eager to seize the moment—and investors’ money.</p>\n<p>All of which is prologue to what could shape up as this cycle’s bell-ringing event, theinitial public offering of Robinhood, the online broker that pioneered zero commissions and hooked a new generation on investing and trading. Thepaperwork was filedwith the SEC this past week. Financial details about the upstart that purports to democratize investing (and, in the process, was hit with a record$70 million fine by Finra, the brokerage business’s self-regulatory body) are discussedhere, but a few salient points are buried deep in the S-1 filing.</p>\n<p>Customer assets more than quadrupled, to $80.9 billion, on March 31 from the total a year earlier, with the lion’s share—some $65.1 billion—accounted for by equities. Options comprised a relatively small $2 billion in assets, but generated nearly half ($197.9 million) of the March quarter’s $420.4 million in transactions revenue. Stocks produced $133.3 million in revenue, even though assets in equities were 40 times as large as those in options. Revenue from cryptocurrencies totaled $87.6 million, with customers’ crypto assets totaling $11.6 billion.</p>\n<p>While Robinhood makes much of opening the market to neophyte investors with limited means by letting them buy fractional shares of their favorite stocks, that’s not its biggest business. Instead, it’s speculative options trading, which exploded early this year especially among the YOLO (You Only Live Once) crowd willing to stake a few bucks on cheap, about-to-expire calls of stocks talked up on Reddit.</p>\n<p>There are signs that the frenzied trading, which peaked during the winter, has eased with the reopening of the economy and the return to the prepandemic normal (and with it an uptick in Covid cases after a steady decline). Trading crypto might be simpler on a brokerage platform like Robinhood, but wasn’t the advantage of DeFi (decentralized finance) supposed to be that intermediaries wouldn’t be needed at all?</p>\n<p>Bulls on Robinhood would be betting on continued growth of its independent trading model, rather than investors using passive funds through advisors, which the filing derides. The broker pledged to reserve up to 35% of its IPO for its customers, who are apt to be enthusiastic buyers and, more importantly, hold onto them with “diamond hands” through volatile times.</p>\n<p>And, indeed, turbulence, or worse, could lie ahead,Michael Burry told our colleague Connor Smith. Burry, a key player in both the book and film versions of<i>The Big Short</i>, won a fortune by betting against the housing market before the subprime mortgage collapse. More recently, he was an early bull onGamestop(ticker: GME), but took his profits in 2020’s fourth quarter before the frenzy around the original meme stock took off. Now he’s warning that the craze will end in tears.</p>\n<p>“I don’t know when meme stocks such as this will crash, but we probably do not have to wait too long, as I believe the retail crowd is fully invested in this theme, and Wall Street has jumped on the coattails,” he told Connor in an email. “We’re running out of new money available to jump on the bandwagon.”</p>\n<p>The Robinhood offering wouldn’t be the first stock sale that could be a top-of-the-market event. Back in mid-2007,<i>Barron’s</i>Andrew Bary calledthe IPO ofBlackstone Group(BX) precisely that, just weeks before concerns about excesses of subprime lending rumbled through the global money markets and months before theDow Jones Industrial Averagepeaked the following October.</p>\n<p>And who could forget the parade of wacky IPOs in the late 1990s that presaged the potential of the internet, but lacked earnings or revenue or even a viable business plan? By March 2000,<i>Barron’s</i>published itsseminal cover storyrevealing that these dot-com darlings were rapidly burning cash. That very month marked theNasdaq Composite’speak; the index would fall nearly 80% by October 2002.</p>\n<p>While Burry warns of a crash in meme stocks from their vastly elevated levels, which some of the companies have exploited by issuing richly valued shares, the overall market—now trading at about 21.5 times estimated earnings for the next 12 months—hasn’t approached the bubble levels of past cycles. But surveys of market strategists and institutional investors see little upside, with year-end targets averaging around 4200 on theS&amp;P 500—shy of Thursday’s close of 4319.</p>\n<p>And while it’s always dangerous to say this, it<i>is</i>different this time around from 2000 and 2008. Ahead of crashes in those years, the Federal Reserve had been tightening policy for some time, resulting in a flat-to-negatively sloped yield curve. Shorter-term Treasury yields were pushed above longer-term ones, leading the bond market to predict that the economy was headed for the rocks.</p>\n<p>Now, in contrast, the Fed has only begun talking about talking about reducing its massive purchases of Treasury and agency mortgage-backed securities. That would be preparation for the initial liftoff of the Fed’s key federal-funds target rate, currently in a rock-bottom 0% to 0.25% range, in 2022 at the earliest and maybe not until 2023.</p>\n<p>The yield curve has flattened a bit in the past three months, with thespread between the two- and 10-year notenarrowing to 1.23 percentage points (still a sign of an accommodative policy), from 1.59 points on March 29, according to the St. Louis Fed.</p>\n<p>But there is also a psychological element at play in any market frenzy. “Most investors also seem to view the stock market as a force of nature itself. They do not fully realize that they themselves, as a group, determine the level of the market,” Nobel laureate Robert Shiller wrote in his now-classic book<i>Irrational Exuberance</i>.</p>\n<p>“In short, the price level is driven to a certain extent by a self-fulfilling prophecy, based on similar hunches held by a vast cross-section of large and small investors and reinforced by news media that are often content to ratify this investor-induced conventional wisdom.”</p>\n<p>Readers can weigh the relevance of the point about traders’ hunches to the Robinhood IPO. As for the latter statement regarding the media, we demur; contrary opinion rather than conventional wisdom has been<i>Barron’s</i>credo in the century since its founding.</p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Robinhood’s IPO Could Be a Sign the Stock Market Has Peaked</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRobinhood’s IPO Could Be a Sign the Stock Market Has Peaked\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-03 10:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/analyst-explains-why-netflix-should-sell-ads-51624987059><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nothing succeeds like excess, as the old quip goes. Until it doesn’t, which has been the distinguishing aspect of market cycles forever and, most dramatically, in this century. Unlike last year’s ...</p>\n\n<a href=\"https://www.barrons.com/articles/analyst-explains-why-netflix-should-sell-ads-51624987059\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index","SPY":"标普500ETF",".IXIC":"NASDAQ Composite",".DJI":"道琼斯"},"source_url":"https://www.barrons.com/articles/analyst-explains-why-netflix-should-sell-ads-51624987059","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1114445293","content_text":"Nothing succeeds like excess, as the old quip goes. Until it doesn’t, which has been the distinguishing aspect of market cycles forever and, most dramatically, in this century. Unlike last year’s pandemic-induced paroxysm, the 2000 bursting of the dot-com bubble and the 2008 financial crisis were marked by initial public offerings by companies eager to seize the moment—and investors’ money.\nAll of which is prologue to what could shape up as this cycle’s bell-ringing event, theinitial public offering of Robinhood, the online broker that pioneered zero commissions and hooked a new generation on investing and trading. Thepaperwork was filedwith the SEC this past week. Financial details about the upstart that purports to democratize investing (and, in the process, was hit with a record$70 million fine by Finra, the brokerage business’s self-regulatory body) are discussedhere, but a few salient points are buried deep in the S-1 filing.\nCustomer assets more than quadrupled, to $80.9 billion, on March 31 from the total a year earlier, with the lion’s share—some $65.1 billion—accounted for by equities. Options comprised a relatively small $2 billion in assets, but generated nearly half ($197.9 million) of the March quarter’s $420.4 million in transactions revenue. Stocks produced $133.3 million in revenue, even though assets in equities were 40 times as large as those in options. Revenue from cryptocurrencies totaled $87.6 million, with customers’ crypto assets totaling $11.6 billion.\nWhile Robinhood makes much of opening the market to neophyte investors with limited means by letting them buy fractional shares of their favorite stocks, that’s not its biggest business. Instead, it’s speculative options trading, which exploded early this year especially among the YOLO (You Only Live Once) crowd willing to stake a few bucks on cheap, about-to-expire calls of stocks talked up on Reddit.\nThere are signs that the frenzied trading, which peaked during the winter, has eased with the reopening of the economy and the return to the prepandemic normal (and with it an uptick in Covid cases after a steady decline). Trading crypto might be simpler on a brokerage platform like Robinhood, but wasn’t the advantage of DeFi (decentralized finance) supposed to be that intermediaries wouldn’t be needed at all?\nBulls on Robinhood would be betting on continued growth of its independent trading model, rather than investors using passive funds through advisors, which the filing derides. The broker pledged to reserve up to 35% of its IPO for its customers, who are apt to be enthusiastic buyers and, more importantly, hold onto them with “diamond hands” through volatile times.\nAnd, indeed, turbulence, or worse, could lie ahead,Michael Burry told our colleague Connor Smith. Burry, a key player in both the book and film versions ofThe Big Short, won a fortune by betting against the housing market before the subprime mortgage collapse. More recently, he was an early bull onGamestop(ticker: GME), but took his profits in 2020’s fourth quarter before the frenzy around the original meme stock took off. Now he’s warning that the craze will end in tears.\n“I don’t know when meme stocks such as this will crash, but we probably do not have to wait too long, as I believe the retail crowd is fully invested in this theme, and Wall Street has jumped on the coattails,” he told Connor in an email. “We’re running out of new money available to jump on the bandwagon.”\nThe Robinhood offering wouldn’t be the first stock sale that could be a top-of-the-market event. Back in mid-2007,Barron’sAndrew Bary calledthe IPO ofBlackstone Group(BX) precisely that, just weeks before concerns about excesses of subprime lending rumbled through the global money markets and months before theDow Jones Industrial Averagepeaked the following October.\nAnd who could forget the parade of wacky IPOs in the late 1990s that presaged the potential of the internet, but lacked earnings or revenue or even a viable business plan? By March 2000,Barron’spublished itsseminal cover storyrevealing that these dot-com darlings were rapidly burning cash. That very month marked theNasdaq Composite’speak; the index would fall nearly 80% by October 2002.\nWhile Burry warns of a crash in meme stocks from their vastly elevated levels, which some of the companies have exploited by issuing richly valued shares, the overall market—now trading at about 21.5 times estimated earnings for the next 12 months—hasn’t approached the bubble levels of past cycles. But surveys of market strategists and institutional investors see little upside, with year-end targets averaging around 4200 on theS&P 500—shy of Thursday’s close of 4319.\nAnd while it’s always dangerous to say this, itisdifferent this time around from 2000 and 2008. Ahead of crashes in those years, the Federal Reserve had been tightening policy for some time, resulting in a flat-to-negatively sloped yield curve. Shorter-term Treasury yields were pushed above longer-term ones, leading the bond market to predict that the economy was headed for the rocks.\nNow, in contrast, the Fed has only begun talking about talking about reducing its massive purchases of Treasury and agency mortgage-backed securities. That would be preparation for the initial liftoff of the Fed’s key federal-funds target rate, currently in a rock-bottom 0% to 0.25% range, in 2022 at the earliest and maybe not until 2023.\nThe yield curve has flattened a bit in the past three months, with thespread between the two- and 10-year notenarrowing to 1.23 percentage points (still a sign of an accommodative policy), from 1.59 points on March 29, according to the St. Louis Fed.\nBut there is also a psychological element at play in any market frenzy. “Most investors also seem to view the stock market as a force of nature itself. They do not fully realize that they themselves, as a group, determine the level of the market,” Nobel laureate Robert Shiller wrote in his now-classic bookIrrational Exuberance.\n“In short, the price level is driven to a certain extent by a self-fulfilling prophecy, based on similar hunches held by a vast cross-section of large and small investors and reinforced by news media that are often content to ratify this investor-induced conventional wisdom.”\nReaders can weigh the relevance of the point about traders’ hunches to the Robinhood IPO. As for the latter statement regarding the media, we demur; contrary opinion rather than conventional wisdom has beenBarron’scredo in the century since its founding.","news_type":1},"isVote":1,"tweetType":1,"viewCount":91,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":846098273,"gmtCreate":1636033996643,"gmtModify":1636034004896,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"Please go up up up","listText":"Please go up up up","text":"Please go up up up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/846098273","repostId":"1107936396","repostType":4,"repost":{"id":"1107936396","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636033656,"share":"https://www.laohu8.com/m/news/1107936396?lang=&edition=full","pubTime":"2021-11-04 21:47","market":"us","language":"en","title":"EV stocks climbed in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1107936396","media":"Tiger Newspress","summary":"EV stocks climbed in morning trading.Tesla,Nio,Xpeng Motors,Li Auto,Nikola&nbsp;and&nbsp;Lordstown&nbsp;rose&nbsp;between 1% and 4%.","content":"<p>EV stocks climbed in morning trading.Tesla,Nio,Xpeng Motors,Li Auto,Nikola&nbsp;and&nbsp;Lordstown&nbsp;rose&nbsp;between 1% and 4%.</p>\n<p><img src=\"https://static.tigerbbs.com/e14b7478da56a6589e4e564ba13f7bbc\" tg-width=\"402\" tg-height=\"475\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EV stocks climbed in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEV stocks climbed in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-04 21:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>EV stocks climbed in morning trading.Tesla,Nio,Xpeng Motors,Li Auto,Nikola&nbsp;and&nbsp;Lordstown&nbsp;rose&nbsp;between 1% and 4%.</p>\n<p><img src=\"https://static.tigerbbs.com/e14b7478da56a6589e4e564ba13f7bbc\" tg-width=\"402\" tg-height=\"475\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XPEV":"小鹏汽车","TSLA":"特斯拉","NIO":"蔚来","LI":"理想汽车"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1107936396","content_text":"EV stocks climbed in morning trading.Tesla,Nio,Xpeng Motors,Li Auto,Nikola and Lordstown rose between 1% and 4%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":979,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":813597160,"gmtCreate":1630211287050,"gmtModify":1704957106811,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"Please like","listText":"Please like","text":"Please like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/813597160","repostId":"1162964424","repostType":4,"repost":{"id":"1162964424","kind":"news","pubTimestamp":1630111098,"share":"https://www.laohu8.com/m/news/1162964424?lang=&edition=full","pubTime":"2021-08-28 08:38","market":"us","language":"en","title":"Apple Stock: How It Could Be A Great Inflation Play","url":"https://stock-news.laohu8.com/highlight/detail?id=1162964424","media":"TheStreet","summary":"Apple’s iPhone 13 could cost consumers more due to an increase in the price of certain components. This is bad news for users, but probably good news for Apple stock investors.IPhone users thinking of upgrading their devices this year  should expect to reach deeper into their pockets. DigiTimes has reported that Apple’s iPhone 13 could be launched next month at a higher price due to parts inflation.Bad news for consumers could be great news for Apple stock investors. If the price increase is con","content":"<p>Apple’s iPhone 13 could cost consumers more due to an increase in the price of certain components. This is bad news for users, but probably good news for Apple stock investors.</p>\n<p>IPhone users thinking of upgrading their devices this year (or those looking to switch to the iOS-based product) should expect to reach deeper into their pockets. DigiTimes has&nbsp;reported&nbsp;that Apple’s iPhone 13 could be launched next month at a higher price due to parts inflation.</p>\n<p>Bad news for consumers could be great news for Apple stock&nbsp;investors. If the price increase is confirmed, it provides evidence that AAPL might be a great inflation play during these times of worry over rising producer and consumer prices.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d6f4ac9ebc1b90072340731dc5c1e613\" tg-width=\"1240\" tg-height=\"698\" referrerpolicy=\"no-referrer\"><span>Figure 1: Apple's iPhone 12 Pro.</span></p>\n<p><b>What happened?</b></p>\n<p>The iPhone is already considered a pricey tech gadget that can cost as much as $1,400 for the fully loaded, higher-end 12 Pro Max model in the US (see figure below). Due to this year’s components shortage, chip maker TSMC may raise its part prices to Apple by 3% to 5%, which could lead to a similar increase in the price of the yet-to-be-announced iPhone 13.</p>\n<p>It is unlikely that one of the largest and most successful consumer product companies in the world would try to raise prices without confidence that doing so does not impact demand for the new iPhone substantially. Apple can probably afford to hike prices because the company understands the value and the appeal of its luxury brand.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0140b9b68bb9eb5dd7e88aaff384785d\" tg-width=\"707\" tg-height=\"370\" referrerpolicy=\"no-referrer\"><span>Figure 2: iPhone 12 Pro on Apple's store.</span></p>\n<p><b>A quote from Jim Cramer</b></p>\n<p>One of the most concerning headwinds to stocks in the foreseeable future is the possibility of inflation eroding corporate margins and leading to higher interest rates in 2021-2022. But should producer and consumer prices spike, not all stocks will be impacted equally.</p>\n<p>Generally speaking, companies with strong pricing power that are able to pass on the higher production costs to consumers will likely outperform. This is a point that&nbsp;Mad Money’s Jim Cramer has made recently. Here is his quote:</p>\n<blockquote>\n “When you try to think of what’s working in this market... I want you to ask yourself, would you be insensitive to a price increase if the company put one through? [What are] the companies that can raise prices without infuriating you? Go buy their stocks.”\n</blockquote>\n<p><b>The impact to the P&amp;L</b></p>\n<p>Are higher prices a good or a bad thing for a company’s financial performance? The answer is nuanced and depends on a few factors.</p>\n<p>Holding all else constant, higher prices also mean higher revenues (think of the formula for sales: price times quantity). If the increase in price is decoupled from an increase in product or operating costs, then the hike also helps to boost margins – thus profits as well.</p>\n<p>However, “holding all else constant” is not how the world really works. A change in price tends to have an impact on a few key variables, most important of which is demand. If higher prices do not impact units sold by much or at all, this is great news for revenues and, most likely, earnings.</p>\n<p>The other piece to consider is whether the price hike fully or only partially offsets higher costs. Assuming the latter, revenues can still benefit without a corresponding positive effect on margins and profits. The complexity presented by the many moving parts makes it hard to determine with certainty how a more expensive iPhone may impact Apple’s financial statements in the future.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple Stock: How It Could Be A Great Inflation Play</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple Stock: How It Could Be A Great Inflation Play\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-28 08:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/apple/iphone/apple-stock-how-it-could-be-a-great-inflation-play><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Apple’s iPhone 13 could cost consumers more due to an increase in the price of certain components. This is bad news for users, but probably good news for Apple stock investors.\nIPhone users thinking ...</p>\n\n<a href=\"https://www.thestreet.com/apple/iphone/apple-stock-how-it-could-be-a-great-inflation-play\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.thestreet.com/apple/iphone/apple-stock-how-it-could-be-a-great-inflation-play","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1162964424","content_text":"Apple’s iPhone 13 could cost consumers more due to an increase in the price of certain components. This is bad news for users, but probably good news for Apple stock investors.\nIPhone users thinking of upgrading their devices this year (or those looking to switch to the iOS-based product) should expect to reach deeper into their pockets. DigiTimes has reported that Apple’s iPhone 13 could be launched next month at a higher price due to parts inflation.\nBad news for consumers could be great news for Apple stock investors. If the price increase is confirmed, it provides evidence that AAPL might be a great inflation play during these times of worry over rising producer and consumer prices.\nFigure 1: Apple's iPhone 12 Pro.\nWhat happened?\nThe iPhone is already considered a pricey tech gadget that can cost as much as $1,400 for the fully loaded, higher-end 12 Pro Max model in the US (see figure below). Due to this year’s components shortage, chip maker TSMC may raise its part prices to Apple by 3% to 5%, which could lead to a similar increase in the price of the yet-to-be-announced iPhone 13.\nIt is unlikely that one of the largest and most successful consumer product companies in the world would try to raise prices without confidence that doing so does not impact demand for the new iPhone substantially. Apple can probably afford to hike prices because the company understands the value and the appeal of its luxury brand.\nFigure 2: iPhone 12 Pro on Apple's store.\nA quote from Jim Cramer\nOne of the most concerning headwinds to stocks in the foreseeable future is the possibility of inflation eroding corporate margins and leading to higher interest rates in 2021-2022. But should producer and consumer prices spike, not all stocks will be impacted equally.\nGenerally speaking, companies with strong pricing power that are able to pass on the higher production costs to consumers will likely outperform. This is a point that Mad Money’s Jim Cramer has made recently. Here is his quote:\n\n “When you try to think of what’s working in this market... I want you to ask yourself, would you be insensitive to a price increase if the company put one through? [What are] the companies that can raise prices without infuriating you? Go buy their stocks.”\n\nThe impact to the P&L\nAre higher prices a good or a bad thing for a company’s financial performance? The answer is nuanced and depends on a few factors.\nHolding all else constant, higher prices also mean higher revenues (think of the formula for sales: price times quantity). If the increase in price is decoupled from an increase in product or operating costs, then the hike also helps to boost margins – thus profits as well.\nHowever, “holding all else constant” is not how the world really works. A change in price tends to have an impact on a few key variables, most important of which is demand. If higher prices do not impact units sold by much or at all, this is great news for revenues and, most likely, earnings.\nThe other piece to consider is whether the price hike fully or only partially offsets higher costs. Assuming the latter, revenues can still benefit without a corresponding positive effect on margins and profits. The complexity presented by the many moving parts makes it hard to determine with certainty how a more expensive iPhone may impact Apple’s financial statements in the future.","news_type":1},"isVote":1,"tweetType":1,"viewCount":93,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":830045185,"gmtCreate":1628996154647,"gmtModify":1633688082396,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"Please like","listText":"Please like","text":"Please like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/830045185","repostId":"2159145532","repostType":4,"repost":{"id":"2159145532","kind":"highlight","pubTimestamp":1628993103,"share":"https://www.laohu8.com/m/news/2159145532?lang=&edition=full","pubTime":"2021-08-15 10:05","market":"us","language":"en","title":"AMC's \"Better\" Isn't the Same Thing as \"Good\"","url":"https://stock-news.laohu8.com/highlight/detail?id=2159145532","media":"Motley Fool","summary":"The theater chain's recently ended quarter serves up the expected glimmer of a recovery, but things are still nowhere near normal.","content":"<p>The good news is movie theater chain <b>AMC Entertainment Holdings</b> (NYSE:AMC) topped last quarter's revenue and earnings estimates. The bad news is it's still deep in the red, and only selling a fraction of the number of tickets it was selling before the pandemic took hold.</p>\n<p>None of this is terribly shocking, of course. A year earlier, the world was largely shut down due to COVID-19. Though the contagion is still with us, consumers and businesses alike are coping. Theaters in the U.S. were mostly reopened by March -- before AMC's second quarter began -- and studios were at least willing to give theaters a try. Universal's <i>Fast and Furious</i> series entry <i>F9</i>&nbsp;debuted in June, catching the tail end of the quarter in question.<i> A Quiet Place, Part II,</i> and <i>Hitman's Wife's Bodyguard</i> were also released in May and June, respectively. <i>Godzilla vs. Kong</i> was in theaters back in April. They weren't necessarily must-sees, but for newly vaccinated movie-goers ready to get out and do something close to normal again, they were something.</p>\n<p>As it turns out, though, they were still very little. AMC has miles to go before nearing the sort of business it was doing before the coronavirus rattled the world.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f60e80beb92a6bcec1a0ff4dbc1b82bd\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>A still-ugly picture</h2>\n<p>The image below speaks volumes, plotting the number of movie tickets AMC sold every quarter through the quarter ending in June. Also plotted are the company's historical quarterly revenue, adjusted EBITDA, and operating profit (or loss), which is a function of those ticket sales. As the saying goes, read 'em and weep.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F638611%2F081021-amc-fiscal-history.png&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"403\" width=\"100%\" height=\"auto\"><span>Data source: AMC Entertainment Holdings. Chart by author. Fiscal data is in millions. Ticket data is in thousands.</span></p>\n<p>Last quarter's 22.1 million tickets sold is around a fourth of the company's usual quarterly ticket sales, around 90 million. Q2's revenue of $444.7 million is roughly a third of the normal figure of $1.3 billion. The most recent results are clearly better than the non-existent numbers being produced a year ago, but still, we're miles away from the pre-pandemic norm. The company's also still deep in the red, reporting an operating loss of $296.6 million and negative adjusted EBITDA of $150.8 million.</p>\n<p>Neither the numbers nor the trend should be surprising, even if analysts and investors alike could only make broad guesses given that the turnaround remains a work in progress. Any revenue and earnings estimate that's even close to the actual reported figure is impressive in light of the circumstances.</p>\n<p>The earnings beat itself, however, has largely obscured more important matters and left important questions unanswered. Chief among these questions is, how much longer will it take the entire movie industry to crawl all the way out of the hole it's still clearly in?</p>\n<h2>From sizzle to fizzle</h2>\n<p>The release of <i>F9</i> in June drew patrons back to theaters, to be sure. Box Office Mojo reports domestic ticket sales of nearly $99 million for that late-June weekend, which was the best weekend the business had seen since February of last year.&nbsp;<b>Walt Disney</b>'s (NYSE:DIS) <i>Black Widow</i> led an even better weekend in early July, leading to $117 million worth of ticket sales in the U.S.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e24f62e8ffec16871093643907bf6e1f\" tg-width=\"700\" tg-height=\"406\" width=\"100%\" height=\"auto\"><span>Data source: Box Office Mojo. Chart by author.</span></p>\n<p>Things have clearly cooled off in the meantime, however, despite reasonably splashy titles like<i> Jungle Cruise, Space Jam: A New Legacy</i>, and <i>The Suicide Squad</i> being in theaters. <i>Hitman's Wife's Bodyguard</i> and <i>A Quiet Place, Part II</i> are also still in theaters, offering at least something theatrical to a wide audience. Consumers just aren't as stoked about going to the movies as they were a month ago.</p>\n<p>Can AMC explain these gloomy trends with the resurgence of COVID-19 via the delta variant? Sure, that's a headwind that can't be ignored. Something else that can't be ignored, however, is the fact that<i> Jungle Cruise, The Suicide Squad, Space Jam: A New Legacy, Black Widow,</i> and <i>F9</i> can all be streamed at home.</p>\n<h2>Bottom line</h2>\n<p>This isn't a forecast for a complete collapse of AMC. One way or another, the theater chain will carry on. It may require some sort of reorganization or debt restructuring, but the name will survive.</p>\n<p>The return to normalcy (or profitability) is at least several quarters away, though, and that could be a few rough quarters. In the meantime, this company has to justify an $18.5 billion market cap, never having produced more than a billion dollars' worth of EBITDA in any four-quarter stretch and never having turned an annualized operating profit of more than $265 million in any four-quarter span -- even in its 2018 heyday.</p>\n<p>At the very least, AMC investors should exercise caution. These investors should also start asking exactly how AMC is going to convince a bunch of consumers to fall out of love with streaming new releases at home. There might not be a good answer to that question.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AMC's \"Better\" Isn't the Same Thing as \"Good\"</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAMC's \"Better\" Isn't the Same Thing as \"Good\"\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-15 10:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/14/amcs-better-isnt-the-same-thing-as-good/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The good news is movie theater chain AMC Entertainment Holdings (NYSE:AMC) topped last quarter's revenue and earnings estimates. The bad news is it's still deep in the red, and only selling a fraction...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/14/amcs-better-isnt-the-same-thing-as-good/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/08/14/amcs-better-isnt-the-same-thing-as-good/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2159145532","content_text":"The good news is movie theater chain AMC Entertainment Holdings (NYSE:AMC) topped last quarter's revenue and earnings estimates. The bad news is it's still deep in the red, and only selling a fraction of the number of tickets it was selling before the pandemic took hold.\nNone of this is terribly shocking, of course. A year earlier, the world was largely shut down due to COVID-19. Though the contagion is still with us, consumers and businesses alike are coping. Theaters in the U.S. were mostly reopened by March -- before AMC's second quarter began -- and studios were at least willing to give theaters a try. Universal's Fast and Furious series entry F9 debuted in June, catching the tail end of the quarter in question. A Quiet Place, Part II, and Hitman's Wife's Bodyguard were also released in May and June, respectively. Godzilla vs. Kong was in theaters back in April. They weren't necessarily must-sees, but for newly vaccinated movie-goers ready to get out and do something close to normal again, they were something.\nAs it turns out, though, they were still very little. AMC has miles to go before nearing the sort of business it was doing before the coronavirus rattled the world.\nImage source: Getty Images.\nA still-ugly picture\nThe image below speaks volumes, plotting the number of movie tickets AMC sold every quarter through the quarter ending in June. Also plotted are the company's historical quarterly revenue, adjusted EBITDA, and operating profit (or loss), which is a function of those ticket sales. As the saying goes, read 'em and weep.\nData source: AMC Entertainment Holdings. Chart by author. Fiscal data is in millions. Ticket data is in thousands.\nLast quarter's 22.1 million tickets sold is around a fourth of the company's usual quarterly ticket sales, around 90 million. Q2's revenue of $444.7 million is roughly a third of the normal figure of $1.3 billion. The most recent results are clearly better than the non-existent numbers being produced a year ago, but still, we're miles away from the pre-pandemic norm. The company's also still deep in the red, reporting an operating loss of $296.6 million and negative adjusted EBITDA of $150.8 million.\nNeither the numbers nor the trend should be surprising, even if analysts and investors alike could only make broad guesses given that the turnaround remains a work in progress. Any revenue and earnings estimate that's even close to the actual reported figure is impressive in light of the circumstances.\nThe earnings beat itself, however, has largely obscured more important matters and left important questions unanswered. Chief among these questions is, how much longer will it take the entire movie industry to crawl all the way out of the hole it's still clearly in?\nFrom sizzle to fizzle\nThe release of F9 in June drew patrons back to theaters, to be sure. Box Office Mojo reports domestic ticket sales of nearly $99 million for that late-June weekend, which was the best weekend the business had seen since February of last year. Walt Disney's (NYSE:DIS) Black Widow led an even better weekend in early July, leading to $117 million worth of ticket sales in the U.S.\nData source: Box Office Mojo. Chart by author.\nThings have clearly cooled off in the meantime, however, despite reasonably splashy titles like Jungle Cruise, Space Jam: A New Legacy, and The Suicide Squad being in theaters. Hitman's Wife's Bodyguard and A Quiet Place, Part II are also still in theaters, offering at least something theatrical to a wide audience. Consumers just aren't as stoked about going to the movies as they were a month ago.\nCan AMC explain these gloomy trends with the resurgence of COVID-19 via the delta variant? Sure, that's a headwind that can't be ignored. Something else that can't be ignored, however, is the fact that Jungle Cruise, The Suicide Squad, Space Jam: A New Legacy, Black Widow, and F9 can all be streamed at home.\nBottom line\nThis isn't a forecast for a complete collapse of AMC. One way or another, the theater chain will carry on. It may require some sort of reorganization or debt restructuring, but the name will survive.\nThe return to normalcy (or profitability) is at least several quarters away, though, and that could be a few rough quarters. In the meantime, this company has to justify an $18.5 billion market cap, never having produced more than a billion dollars' worth of EBITDA in any four-quarter stretch and never having turned an annualized operating profit of more than $265 million in any four-quarter span -- even in its 2018 heyday.\nAt the very least, AMC investors should exercise caution. These investors should also start asking exactly how AMC is going to convince a bunch of consumers to fall out of love with streaming new releases at home. There might not be a good answer to that question.","news_type":1},"isVote":1,"tweetType":1,"viewCount":33,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":898926275,"gmtCreate":1628469672197,"gmtModify":1633747002572,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/898926275","repostId":"1162909436","repostType":4,"repost":{"id":"1162909436","kind":"news","pubTimestamp":1628463995,"share":"https://www.laohu8.com/m/news/1162909436?lang=&edition=full","pubTime":"2021-08-09 07:06","market":"us","language":"en","title":"Disney, AMC, Coinbase, Airbnb, BioNTech, and Other Stocks for Investors to Watch This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=1162909436","media":"Barron's","summary":"The bulk of second-quarter earnings season is in the rearview mirror, but several notable reports re","content":"<p>The bulk of second-quarter earnings season is in the rearview mirror,&nbsp;but several notable reports remain.&nbsp;AMC Entertainment Holdings,&nbsp;BioNTech, and&nbsp;Dish Network&nbsp;will be Monday’s highlights.&nbsp;Coinbase&nbsp;Global and&nbsp;Syscogo on Tuesday. On Wednesday,&nbsp;eBay&nbsp;will report, followed by Walt&nbsp;Disney,&nbsp;Airbnb,&nbsp;DoorDash,&nbsp;and&nbsp;Broadridge Financial Solutionson Thursday.</p>\n<p>The week’s economic calendar will include a pair of updates each on consumer and business inflation and sentiment. On Wednesday, the Bureau of Labor Statistics will&nbsp;report&nbsp;the consumer price index for July, followed by the producer price index on Thursday. Those are expected to have increased by 5.3% and 7.3%, respectively, year over year.</p>\n<p>On Tuesday, the National Federation of Independent Business will release its Small Business Optimism Index for July. And on Friday, the University of Michigan reports its Consumer Sentiment index for August. Both are forecast to hold roughly even with the prior months’ figures.</p>\n<h3><b>Monday 8/9</b></h3>\n<p>Air Products and Chemicals,&nbsp;<a href=\"https://laohu8.com/S/AMC\">AMC Entertainment</a>,&nbsp;Barrick Gold,&nbsp;<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>, <a href=\"https://laohu8.com/S/DISH\">DISH Network</a>, and&nbsp;<a href=\"https://laohu8.com/S/TSN\">Tyson</a>&nbsp;report quarterly results.</p>\n<p><b>The Bureau of Labor Statistics</b>&nbsp;reports the Job Openings and Labor Turnover Survey for June. Economists forecast 9.1 million openings on the last business day of June, slightly less than the May figure. Job openings stand at record levels as employers struggle to fill vacant positions.</p>\n<h3><b>Tuesday 8/10</b></h3>\n<p><b>The National Federation of Independent Business</b>&nbsp;reports its Small Business Optimism Index for July. Consensus estimate is for a 102.8 reading, roughly even with the June data, which was the highest since October.</p>\n<p><a href=\"https://laohu8.com/S/COIN\">Coinbase Global, Inc.</a>, <a href=\"https://laohu8.com/S/SYY\">Sysco</a>, and&nbsp;<a href=\"https://laohu8.com/S/TDG\">TransDigm</a> announce earnings.</p>\n<p><b>The BLS reports unit labor</b>&nbsp;costs and nonfarm productivity for the second quarter. Expectations are for a rise of 0.9% in labor costs and 3.4% for productivity. This compares with increases of 1.7% and 5.4%, respectively, in the first quarter.</p>\n<h3><b>Wednesday 8/11</b></h3>\n<p><a href=\"https://laohu8.com/S/EBAY\">eBay</a> and&nbsp;<a href=\"https://laohu8.com/S/PRGO\">Perrigo Co PLC</a> release quarterly results.</p>\n<p><b>The BLS reports the consumer</b>&nbsp;price index for July. Economists forecast a 5.3% increase year over year, after a gain of 5.4% in June. The core CPI, which excludes volatile food and energy prices, is expected to rise 4.3%, compared with 4.5% previously. Inflation, and whether it is transitory, has generated much discussion on Wall Street this year, with the June CPI showing the fastest pace of growth since July 2008 and core CPI rising at the swiftest clip in nearly 30 years.</p>\n<p><b>The Treasury Department</b>&nbsp;releases the monthly budget statement for July. The estimated deficit is $267 billion for the month, and $3 trillion for fiscal 2021, which ends in September. The $3 trillion would be just shy of fiscal 2020’s $3.1 trillion deficit, a record.</p>\n<h3><b>Thursday 8/12</b></h3>\n<p><a href=\"https://laohu8.com/S/ABNB\">Airbnb, Inc.</a>, <a href=\"https://laohu8.com/S/BR\">Broadridge Financial Solutions</a>,&nbsp;<a href=\"https://laohu8.com/S/BAM\">Brookfield Asset Management</a>,&nbsp;<a href=\"https://laohu8.com/S/DASH\">DoorDash, Inc.</a>, and <a href=\"https://laohu8.com/S/DIS\">Walt Disney</a> hold conference calls to discuss earnings.</p>\n<p>Idexx Laboratorieshosts its 2021 virtual investor day.</p>\n<p><b>The BLS reports the</b>&nbsp;producer price index for July. Consensus estimate is for a 0.4% month-over-month rise. The core PPI, which excludes volatile food and energy prices, is projected to increase 0.5%. The PPI and core PPI, both jumped 1% in June.</p>\n<p><b>The Department of Labor</b>&nbsp;reports initial jobless claims for the weekend ending on Aug. 7. In July, claims averaged 392,000 a week, slightly less than the June data. Jobless claims have trended down since peaking in the spring of 2020 but remain elevated compared with prepandemic levels.</p>\n<h3><b>Friday 8/13</b></h3>\n<p><b>The University of Michigan</b>&nbsp;releases its Consumer Sentiment index for August. Expectations are for an 81.1 reading, roughly even with the July figure.</p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Disney, AMC, Coinbase, Airbnb, BioNTech, and Other Stocks for Investors to Watch This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDisney, AMC, Coinbase, Airbnb, BioNTech, and Other Stocks for Investors to Watch This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-09 07:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/disney-amc-coinbase-airbnb-biontech-and-other-stocks-for-investors-to-watch-this-week-51628449233?mod=hp_LEAD_4?mod=article_signInButton><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The bulk of second-quarter earnings season is in the rearview mirror, but several notable reports remain. AMC Entertainment Holdings, BioNTech, and Dish Network will be Monday’s highlights. Coinbase ...</p>\n\n<a href=\"https://www.barrons.com/articles/disney-amc-coinbase-airbnb-biontech-and-other-stocks-for-investors-to-watch-this-week-51628449233?mod=hp_LEAD_4?mod=article_signInButton\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DIS":"迪士尼","COIN":"Coinbase Global, Inc.",".IXIC":"NASDAQ Composite","BAM":"布鲁克菲尔德资产管理","TDG":"TransDigm","ABNB":"爱彼迎",".SPX":"S&P 500 Index","AMC":"AMC院线","EBAY":"eBay","BR":"Broadridge金融解决方案",".DJI":"道琼斯","PRGO":"百利高"},"source_url":"https://www.barrons.com/articles/disney-amc-coinbase-airbnb-biontech-and-other-stocks-for-investors-to-watch-this-week-51628449233?mod=hp_LEAD_4?mod=article_signInButton","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1162909436","content_text":"The bulk of second-quarter earnings season is in the rearview mirror, but several notable reports remain. AMC Entertainment Holdings, BioNTech, and Dish Network will be Monday’s highlights. Coinbase Global and Syscogo on Tuesday. On Wednesday, eBay will report, followed by Walt Disney, Airbnb, DoorDash, and Broadridge Financial Solutionson Thursday.\nThe week’s economic calendar will include a pair of updates each on consumer and business inflation and sentiment. On Wednesday, the Bureau of Labor Statistics will report the consumer price index for July, followed by the producer price index on Thursday. Those are expected to have increased by 5.3% and 7.3%, respectively, year over year.\nOn Tuesday, the National Federation of Independent Business will release its Small Business Optimism Index for July. And on Friday, the University of Michigan reports its Consumer Sentiment index for August. Both are forecast to hold roughly even with the prior months’ figures.\nMonday 8/9\nAir Products and Chemicals, AMC Entertainment, Barrick Gold, BioNTech SE, DISH Network, and Tyson report quarterly results.\nThe Bureau of Labor Statistics reports the Job Openings and Labor Turnover Survey for June. Economists forecast 9.1 million openings on the last business day of June, slightly less than the May figure. Job openings stand at record levels as employers struggle to fill vacant positions.\nTuesday 8/10\nThe National Federation of Independent Business reports its Small Business Optimism Index for July. Consensus estimate is for a 102.8 reading, roughly even with the June data, which was the highest since October.\nCoinbase Global, Inc., Sysco, and TransDigm announce earnings.\nThe BLS reports unit labor costs and nonfarm productivity for the second quarter. Expectations are for a rise of 0.9% in labor costs and 3.4% for productivity. This compares with increases of 1.7% and 5.4%, respectively, in the first quarter.\nWednesday 8/11\neBay and Perrigo Co PLC release quarterly results.\nThe BLS reports the consumer price index for July. Economists forecast a 5.3% increase year over year, after a gain of 5.4% in June. The core CPI, which excludes volatile food and energy prices, is expected to rise 4.3%, compared with 4.5% previously. Inflation, and whether it is transitory, has generated much discussion on Wall Street this year, with the June CPI showing the fastest pace of growth since July 2008 and core CPI rising at the swiftest clip in nearly 30 years.\nThe Treasury Department releases the monthly budget statement for July. The estimated deficit is $267 billion for the month, and $3 trillion for fiscal 2021, which ends in September. The $3 trillion would be just shy of fiscal 2020’s $3.1 trillion deficit, a record.\nThursday 8/12\nAirbnb, Inc., Broadridge Financial Solutions, Brookfield Asset Management, DoorDash, Inc., and Walt Disney hold conference calls to discuss earnings.\nIdexx Laboratorieshosts its 2021 virtual investor day.\nThe BLS reports the producer price index for July. Consensus estimate is for a 0.4% month-over-month rise. The core PPI, which excludes volatile food and energy prices, is projected to increase 0.5%. The PPI and core PPI, both jumped 1% in June.\nThe Department of Labor reports initial jobless claims for the weekend ending on Aug. 7. In July, claims averaged 392,000 a week, slightly less than the June data. Jobless claims have trended down since peaking in the spring of 2020 but remain elevated compared with prepandemic levels.\nFriday 8/13\nThe University of Michigan releases its Consumer Sentiment index for August. Expectations are for an 81.1 reading, roughly even with the July figure.","news_type":1},"isVote":1,"tweetType":1,"viewCount":3,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":801241051,"gmtCreate":1627520452773,"gmtModify":1633764206387,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/801241051","repostId":"2155027927","repostType":4,"isVote":1,"tweetType":1,"viewCount":26,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":177833566,"gmtCreate":1627193457555,"gmtModify":1633767247283,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/177833566","repostId":"1176552691","repostType":4,"repost":{"id":"1176552691","kind":"news","pubTimestamp":1627183789,"share":"https://www.laohu8.com/m/news/1176552691?lang=&edition=full","pubTime":"2021-07-25 11:29","market":"us","language":"en","title":"Is IBM Stock Undervalued Or Overvalued? What To Consider","url":"https://stock-news.laohu8.com/highlight/detail?id=1176552691","media":"seekingalpha","summary":"Summary\n\nIBM beat analysts’ second-quarter earnings as cloud revenue and operating margins improved.","content":"<p><b>Summary</b></p>\n<ul>\n <li>IBM beat analysts’ second-quarter earnings as cloud revenue and operating margins improved.</li>\n <li>Prior to Q1, IBM posted declining revenue for four consecutive quarters, and 30 of the last 34 quarters.</li>\n <li>More transparency is needed regarding the Kyndryl spinoff.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2c798e0536c6804d44b195f6f349fab5\" tg-width=\"1536\" tg-height=\"1044\" width=\"100%\" height=\"auto\"><span>Ethan Miller/Getty Images News</span></p>\n<p>International Business Machines Corporation (IBM) is a company in transition. Unfortunately for investors, the transition has been in place for the better part of a decade. Those turnaround efforts include investments in cloud computing and artificial intelligence and the divestiture of legacy businesses. While there are now signs of green shoots, it is yet to be seen as to whether the seeds sown have fallen on rocky ground.</p>\n<p>Although the company has a rapidly growing business in hybrid cloud offerings, and a potential growth engine in quantum computing, it faces intense competition in the former industry and uncertain prospects in the latter. Most of the firm’s other businesses are in the doldrums, so IBM’s growth prospects are opaque.</p>\n<p>What is certain is that as of today, IBM has a reasonable and diminishing debt load and strong free cash flow.</p>\n<p>Management is attempting to address growth concerns in part by focusing on the firm’s cloud offerings, while it spins off its managed infrastructure business. That company will be named Kyndryl. However, the debt which the new entity will shoulder, along with the portion of the current dividend that it will carry, has not been divulged.</p>\n<p><b>Recent Quarterly Results</b></p>\n<p>IBM&nbsp;reported&nbsp;Q2 results last Monday. With non-GAAP EPS of $2.33, the company beat estimates by $0.04.</p>\n<p>Revenue of $18.7 billion was flat when adjusted for currency and divestitures.</p>\n<p>The negative side of the report had Systems revenue declining by 7%. However, this was largely due to the normal IBM Z mainframe cycle, down 13% year over year.</p>\n<p>The global financing division, which represents a low single digit percentage of overall revenues, was down 9%. Global technology services, which represents roughly a third of overall revenue and will largely be spun off as Kyndryl, had flattish growth.</p>\n<p>The positive side of the report had Cloud &amp; Cognitive Software cloud revenue up 29% and Global Business Services cloud revenue up 35%. Total cloud revenue of $27 billion increased by 15% over the last 12 months, while cloud revenue grew 13% in the quarter to $7.0 billion.</p>\n<p>Net cash from operating activities hit $17.7 billion, and adjusted free cash flow totaled $11 billion over the last 12 months.</p>\n<p>Since year-end 2020, the company has reduced debt by $6.4 billion.</p>\n<p>Management guides for adjusted free cash flow of $11 billion to $12 billion in 2021.</p>\n<p><b>Where IBM Stands Tall</b></p>\n<p>IBM is viewed by many as at best a third rate IT company and at worst as a dinosaur, headed towards extinction.</p>\n<p>It is evident that the company’s revenues have declined for years; however, to accurately assess the stock, investors must understand that IBM’s legacy businesses have many strengths.</p>\n<p>For example, IBM is the world’s largest IT services company and the dominant provider of mainframes. Among the Fortune 50 companies, 47 are IBM clients.</p>\n<p>Half of the world’s wireless connections are handled by the firm.</p>\n<p>IBM's mainframe systems process nearly 90% of the globe’s credit card transactions, and 97% of the world's largest banks rely on IBM products and services. Consequently, twenty-nine billion ATM transactions are processed annually using IBM systems.</p>\n<p>Eight out of 10 global retailers rely on IBM products and services while 80% of the travel industry's reservations run through IBM systems. That results in 4 billion flight reservations being processed using the company’s IT services.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/7ace4f1436fd2697c5ad266b5017e1dd\" tg-width=\"960\" tg-height=\"721\" width=\"100%\" height=\"auto\"><span>Source: Forbes</span></p>\n<p>It is evident that IBM has a massive customer base that provides large scale recurring revenues. In many cases, moving to competitors' offerings would mean risking the transfer of sensitive information, a move many are not willing to take.</p>\n<p>However, with the transition to cloud services and open source software, there is an increased adoption by firms of mix and match IT infrastructures. In turn, this is eroding IBM’s competitive advantage associated with customer switching costs.</p>\n<p><b>The Sources Of Potential Growth</b></p>\n<p>Investors are generally aware of IBM's effort to drive growth through its hybrid cloud offerings. However, when questioned at JPMorgan’s recent investor conference, CFO Jim Kavanaugh&nbsp;provided insight&nbsp;into how hybrid cloud drives revenue in some of IBM’s other divisions.</p>\n<blockquote>\n For every $1 (in business) we land on a hybrid cloud platform, we see $3 to $5 of software drag and $6 to $8 of services drag overall.\n</blockquote>\n<p>Of course, Kavanaugh is using drag to refer to increased revenue in software and services associated with adoption of IBM’s hybrid cloud. If Kavanaugh’s claims are accurate, that means every dollar spent on the company’s hybrid cloud platform translates into $9 to $13 in additional revenue from the firm’s software and services offerings.</p>\n<p>Because hybrid cloud uses a mix of on-premises private cloud and public cloud services, it offers clients a degree of data privacy. This is of particular concern for customers in healthcare and financial services. Consequently, I would posit that IBM might have an advantage in competing with other hybrid cloud providers as it has extensive relationships within those industries.</p>\n<p>I reviewed a variety of prognostications regarding projected growth rates for the hybrid cloud market. The most recent study, which also falls in the middle of other predictions, is by Mordor Intelligence. That firm&nbsp;forecasts&nbsp;a CAGR of 18.73% from 2021 through 2026.</p>\n<p>Investors should be aware that the major operators in this space are Cisco (CSCO), Hewlett Packard (HPE), Amazon (AMZN), Citrix Systems (CTXS), and IBM.</p>\n<p>The following chart provides a record of the firm’s total cloud growth over the last six quarters.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/5fc85156e70f6caf8ae809f76126a723\" tg-width=\"576\" tg-height=\"336\" width=\"100%\" height=\"auto\"><span>Source: Company reports / Chart by Author</span></p>\n<p>Aside from cloud, there is another source of potential growth, although it is unlikely to materialize soon.</p>\n<p>Early in 2019, IBM&nbsp;introduced&nbsp;the Q System One. IBM Q systems are the world's first quantum computer designed for scientific and commercial use.</p>\n<p>Pardon the pun, but quantum computers represent a quantum leap in technology. Prescient And Strategic Intelligence&nbsp;forecasts&nbsp;a CAGR of 56% for the industry through 2030 with the quantum computer market share reaching nearly $65 billion.</p>\n<p>For additional insights regarding quantum computing and IBM’s position within that industry, I point you to&nbsp;my article, “IBM: Why My Eye Is Fixed On Big Blue.”</p>\n<p><b>Understanding Kyndryl</b></p>\n<p>Once&nbsp;Kyndryl&nbsp;is launched, it will have more than 90,000 employees and more than 4,600 customers in 115 countries. With a $60 billion services backlog, the new entity will begin with projected revenues of $19 billion. At twice the size of its closest competitor, the company will be the world’s largest managed infrastructure services provider.</p>\n<p>The split will&nbsp;transform&nbsp;IBM from a company that pulls half of its revenue from services to a firm with its software and solutions businesses generating over half of its revenue on a recurring basis.</p>\n<p>Global Business Services, which currently constitutes 22% of the company’s revenue, will&nbsp;account&nbsp;for over 40% of sales. Here it is important to note that the division grew revenue by 12% year over year in the last quarter.</p>\n<p>IBM will retain Red Hat and its solution provider business, the systems businesses, and its mission-critical public cloud service, and a software portfolio focused on big data, AI, and security.</p>\n<p>Initially, the two companies will each be the largest customer of the other.</p>\n<p>What remains to be known regarding the spinoff is how much debt each company will shoulder, and the share of the dividend that the companies will pay. Krishna stated the two companies will work together to sustain the current payout level.</p>\n<p><b>Has IBM Turned The Corner?</b></p>\n<p>Anyone who follows IBM knows the company has experienced an extended period of poor results. The following chart provides a record of the firm’s quarterly FCF over the last fourteen quarters.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/60cc8b82052f97dd449205999ee30711\" tg-width=\"577\" tg-height=\"337\" width=\"100%\" height=\"auto\"><span>Source: Data from ycharts / chart by author</span></p>\n<p>While this is not proof positive that the company is back on track, the recent trend is at least encouraging.</p>\n<p>In 2020, IBM generated $10.8 billion in free cash flow. Management guides for adjusted free cash flow of $11 billion to $12 billion in 2021. This excludes $3 billion in structural impacts related to the Kyndryl spinoff.</p>\n<p>The CEO&nbsp;recently stated&nbsp;he expects IBM to generate $12 billion to $13 billion in FCF in 2022.</p>\n<p><b>Debt And Dividend</b></p>\n<p>While investors can rightfully complain of a variety of management moves over the years, the firm has maintained a reasonable debt profile while engaging in a number of acquisitions.</p>\n<p>The company has reduced the debt by roughly $18 billion since its peak in mid-2019. IBM maintains an investment level credit rating, and the following chart provides a record of the company’s progress paying down debt of late.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b73e613157c486a5f5e8306546121971\" tg-width=\"1280\" tg-height=\"720\" width=\"100%\" height=\"auto\"><span>Source: IBM Presentation</span></p>\n<p>IBM has a yield of 4.64%, a payout ratio a bit below 61%, and a 5 year dividend growth rate of 4.26%. As previously noted, following the spinoff of Kyndryl, the two companies will team to provide a payout equivalent to the current dividend.</p>\n<p><b>Is IBM Stock Overvalued?</b></p>\n<p>IBM shares trade for $141.13. The average 12 month price target of 8 analysts is $153.50. The price target of the 3 analysts rating the stock since the last earnings report is $151.33.</p>\n<p>IBM has a P/E of 24.05x and a forward P/E of 17.67x. This compares to its five year averages of 16.42x and 13.25x respectively. It is well below the sector average which is in the low thirties for both metrics.</p>\n<p>The 3 to 5 year PEG provided by Seeking Alpha Premium is 1.16x. Schwab calculates a PEG of 1.49x, and Yahoo does not provide a PEG ratio.</p>\n<p>I believe the current P/E ratios for the stock reflect investors anticipating increased growth for IBM once the spinoff is complete. The PEG ratios show the stock is reasonably valued.</p>\n<p><b>Is IBM Stock A Good Long-Term Investment?</b></p>\n<p>IBM has an entrenched but evolving position among many of the largest companies on the globe. Unfortunately, the cloud, which is seen as the company’s primary avenue for growth, could also lead to a slow deterioration in some of the firm’s legacy businesses.</p>\n<p>That the cloud business has been growing at a rapid pace is manifest: IBM can now boast of over 3,200 clients using the firm’s hybrid cloud platform. That is nearly four times the number just prior to the Red Hat acquisition.</p>\n<p>If management’s claims are accurate, the hybrid cloud platform will create robust growth in the software and services division’s revenues. When combined with the spinoff of Kyndryl’s slow growing managed infrastructure services business, it is reasonable to believe IBM will witness increased growth.</p>\n<p>IBM has a solid balance sheet, a robust yield, and when viewed using PEG ratios as a basis for valuing the stock, the shares are trading at a bit of a discount.</p>\n<p>All considered, I rate IBM as a BUY.</p>\n<p>I think the worst case short to mid-term scenario is that the company experiences slow growth while investors collect a rather robust dividend.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is IBM Stock Undervalued Or Overvalued? What To Consider</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs IBM Stock Undervalued Or Overvalued? What To Consider\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-25 11:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4440996-is-ibm-stock-undervalued-overvalued><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nIBM beat analysts’ second-quarter earnings as cloud revenue and operating margins improved.\nPrior to Q1, IBM posted declining revenue for four consecutive quarters, and 30 of the last 34 ...</p>\n\n<a href=\"https://seekingalpha.com/article/4440996-is-ibm-stock-undervalued-overvalued\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IBM":"IBM"},"source_url":"https://seekingalpha.com/article/4440996-is-ibm-stock-undervalued-overvalued","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176552691","content_text":"Summary\n\nIBM beat analysts’ second-quarter earnings as cloud revenue and operating margins improved.\nPrior to Q1, IBM posted declining revenue for four consecutive quarters, and 30 of the last 34 quarters.\nMore transparency is needed regarding the Kyndryl spinoff.\n\nEthan Miller/Getty Images News\nInternational Business Machines Corporation (IBM) is a company in transition. Unfortunately for investors, the transition has been in place for the better part of a decade. Those turnaround efforts include investments in cloud computing and artificial intelligence and the divestiture of legacy businesses. While there are now signs of green shoots, it is yet to be seen as to whether the seeds sown have fallen on rocky ground.\nAlthough the company has a rapidly growing business in hybrid cloud offerings, and a potential growth engine in quantum computing, it faces intense competition in the former industry and uncertain prospects in the latter. Most of the firm’s other businesses are in the doldrums, so IBM’s growth prospects are opaque.\nWhat is certain is that as of today, IBM has a reasonable and diminishing debt load and strong free cash flow.\nManagement is attempting to address growth concerns in part by focusing on the firm’s cloud offerings, while it spins off its managed infrastructure business. That company will be named Kyndryl. However, the debt which the new entity will shoulder, along with the portion of the current dividend that it will carry, has not been divulged.\nRecent Quarterly Results\nIBM reported Q2 results last Monday. With non-GAAP EPS of $2.33, the company beat estimates by $0.04.\nRevenue of $18.7 billion was flat when adjusted for currency and divestitures.\nThe negative side of the report had Systems revenue declining by 7%. However, this was largely due to the normal IBM Z mainframe cycle, down 13% year over year.\nThe global financing division, which represents a low single digit percentage of overall revenues, was down 9%. Global technology services, which represents roughly a third of overall revenue and will largely be spun off as Kyndryl, had flattish growth.\nThe positive side of the report had Cloud & Cognitive Software cloud revenue up 29% and Global Business Services cloud revenue up 35%. Total cloud revenue of $27 billion increased by 15% over the last 12 months, while cloud revenue grew 13% in the quarter to $7.0 billion.\nNet cash from operating activities hit $17.7 billion, and adjusted free cash flow totaled $11 billion over the last 12 months.\nSince year-end 2020, the company has reduced debt by $6.4 billion.\nManagement guides for adjusted free cash flow of $11 billion to $12 billion in 2021.\nWhere IBM Stands Tall\nIBM is viewed by many as at best a third rate IT company and at worst as a dinosaur, headed towards extinction.\nIt is evident that the company’s revenues have declined for years; however, to accurately assess the stock, investors must understand that IBM’s legacy businesses have many strengths.\nFor example, IBM is the world’s largest IT services company and the dominant provider of mainframes. Among the Fortune 50 companies, 47 are IBM clients.\nHalf of the world’s wireless connections are handled by the firm.\nIBM's mainframe systems process nearly 90% of the globe’s credit card transactions, and 97% of the world's largest banks rely on IBM products and services. Consequently, twenty-nine billion ATM transactions are processed annually using IBM systems.\nEight out of 10 global retailers rely on IBM products and services while 80% of the travel industry's reservations run through IBM systems. That results in 4 billion flight reservations being processed using the company’s IT services.\nSource: Forbes\nIt is evident that IBM has a massive customer base that provides large scale recurring revenues. In many cases, moving to competitors' offerings would mean risking the transfer of sensitive information, a move many are not willing to take.\nHowever, with the transition to cloud services and open source software, there is an increased adoption by firms of mix and match IT infrastructures. In turn, this is eroding IBM’s competitive advantage associated with customer switching costs.\nThe Sources Of Potential Growth\nInvestors are generally aware of IBM's effort to drive growth through its hybrid cloud offerings. However, when questioned at JPMorgan’s recent investor conference, CFO Jim Kavanaugh provided insight into how hybrid cloud drives revenue in some of IBM’s other divisions.\n\n For every $1 (in business) we land on a hybrid cloud platform, we see $3 to $5 of software drag and $6 to $8 of services drag overall.\n\nOf course, Kavanaugh is using drag to refer to increased revenue in software and services associated with adoption of IBM’s hybrid cloud. If Kavanaugh’s claims are accurate, that means every dollar spent on the company’s hybrid cloud platform translates into $9 to $13 in additional revenue from the firm’s software and services offerings.\nBecause hybrid cloud uses a mix of on-premises private cloud and public cloud services, it offers clients a degree of data privacy. This is of particular concern for customers in healthcare and financial services. Consequently, I would posit that IBM might have an advantage in competing with other hybrid cloud providers as it has extensive relationships within those industries.\nI reviewed a variety of prognostications regarding projected growth rates for the hybrid cloud market. The most recent study, which also falls in the middle of other predictions, is by Mordor Intelligence. That firm forecasts a CAGR of 18.73% from 2021 through 2026.\nInvestors should be aware that the major operators in this space are Cisco (CSCO), Hewlett Packard (HPE), Amazon (AMZN), Citrix Systems (CTXS), and IBM.\nThe following chart provides a record of the firm’s total cloud growth over the last six quarters.\nSource: Company reports / Chart by Author\nAside from cloud, there is another source of potential growth, although it is unlikely to materialize soon.\nEarly in 2019, IBM introduced the Q System One. IBM Q systems are the world's first quantum computer designed for scientific and commercial use.\nPardon the pun, but quantum computers represent a quantum leap in technology. Prescient And Strategic Intelligence forecasts a CAGR of 56% for the industry through 2030 with the quantum computer market share reaching nearly $65 billion.\nFor additional insights regarding quantum computing and IBM’s position within that industry, I point you to my article, “IBM: Why My Eye Is Fixed On Big Blue.”\nUnderstanding Kyndryl\nOnce Kyndryl is launched, it will have more than 90,000 employees and more than 4,600 customers in 115 countries. With a $60 billion services backlog, the new entity will begin with projected revenues of $19 billion. At twice the size of its closest competitor, the company will be the world’s largest managed infrastructure services provider.\nThe split will transform IBM from a company that pulls half of its revenue from services to a firm with its software and solutions businesses generating over half of its revenue on a recurring basis.\nGlobal Business Services, which currently constitutes 22% of the company’s revenue, will account for over 40% of sales. Here it is important to note that the division grew revenue by 12% year over year in the last quarter.\nIBM will retain Red Hat and its solution provider business, the systems businesses, and its mission-critical public cloud service, and a software portfolio focused on big data, AI, and security.\nInitially, the two companies will each be the largest customer of the other.\nWhat remains to be known regarding the spinoff is how much debt each company will shoulder, and the share of the dividend that the companies will pay. Krishna stated the two companies will work together to sustain the current payout level.\nHas IBM Turned The Corner?\nAnyone who follows IBM knows the company has experienced an extended period of poor results. The following chart provides a record of the firm’s quarterly FCF over the last fourteen quarters.\nSource: Data from ycharts / chart by author\nWhile this is not proof positive that the company is back on track, the recent trend is at least encouraging.\nIn 2020, IBM generated $10.8 billion in free cash flow. Management guides for adjusted free cash flow of $11 billion to $12 billion in 2021. This excludes $3 billion in structural impacts related to the Kyndryl spinoff.\nThe CEO recently stated he expects IBM to generate $12 billion to $13 billion in FCF in 2022.\nDebt And Dividend\nWhile investors can rightfully complain of a variety of management moves over the years, the firm has maintained a reasonable debt profile while engaging in a number of acquisitions.\nThe company has reduced the debt by roughly $18 billion since its peak in mid-2019. IBM maintains an investment level credit rating, and the following chart provides a record of the company’s progress paying down debt of late.\nSource: IBM Presentation\nIBM has a yield of 4.64%, a payout ratio a bit below 61%, and a 5 year dividend growth rate of 4.26%. As previously noted, following the spinoff of Kyndryl, the two companies will team to provide a payout equivalent to the current dividend.\nIs IBM Stock Overvalued?\nIBM shares trade for $141.13. The average 12 month price target of 8 analysts is $153.50. The price target of the 3 analysts rating the stock since the last earnings report is $151.33.\nIBM has a P/E of 24.05x and a forward P/E of 17.67x. This compares to its five year averages of 16.42x and 13.25x respectively. It is well below the sector average which is in the low thirties for both metrics.\nThe 3 to 5 year PEG provided by Seeking Alpha Premium is 1.16x. Schwab calculates a PEG of 1.49x, and Yahoo does not provide a PEG ratio.\nI believe the current P/E ratios for the stock reflect investors anticipating increased growth for IBM once the spinoff is complete. The PEG ratios show the stock is reasonably valued.\nIs IBM Stock A Good Long-Term Investment?\nIBM has an entrenched but evolving position among many of the largest companies on the globe. Unfortunately, the cloud, which is seen as the company’s primary avenue for growth, could also lead to a slow deterioration in some of the firm’s legacy businesses.\nThat the cloud business has been growing at a rapid pace is manifest: IBM can now boast of over 3,200 clients using the firm’s hybrid cloud platform. That is nearly four times the number just prior to the Red Hat acquisition.\nIf management’s claims are accurate, the hybrid cloud platform will create robust growth in the software and services division’s revenues. When combined with the spinoff of Kyndryl’s slow growing managed infrastructure services business, it is reasonable to believe IBM will witness increased growth.\nIBM has a solid balance sheet, a robust yield, and when viewed using PEG ratios as a basis for valuing the stock, the shares are trading at a bit of a discount.\nAll considered, I rate IBM as a BUY.\nI think the worst case short to mid-term scenario is that the company experiences slow growth while investors collect a rather robust dividend.","news_type":1},"isVote":1,"tweetType":1,"viewCount":227,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":176948894,"gmtCreate":1626857188418,"gmtModify":1633770365857,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/176948894","repostId":"1179602567","repostType":4,"repost":{"id":"1179602567","kind":"news","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1626854916,"share":"https://www.laohu8.com/m/news/1179602567?lang=&edition=full","pubTime":"2021-07-21 16:08","market":"us","language":"en","title":"ASML rose over 3% in premarket trading, it hikes 2021 sales outlook as chip demand stays strong","url":"https://stock-news.laohu8.com/highlight/detail?id=1179602567","media":"Reuters","summary":"(July 21) ASML Holding NV rose over 3% in premarket trading, it hikes 2021 sales outlook as chip dem","content":"<p>(July&nbsp;21)&nbsp;<a href=\"https://laohu8.com/S/ASML\">ASML Holding NV</a> rose over 3% in premarket trading, it hikes 2021 sales outlook as chip demand stays strong.</p>\n<p><img src=\"https://static.tigerbbs.com/e5b3b8b29b8d681781a613380a8564f3\" tg-width=\"704\" tg-height=\"486\" referrerpolicy=\"no-referrer\"></p>\n<p>ASML, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the biggest suppliers to semiconductor companies worldwide, hiked its 2021 sales outlook on Wednesday and announced a new share buyback, as sales soared amid a global computer chip shortage.</p>\n<p>The Dutch company, which services all major chip makers, such as TSMC, Samsung and <a href=\"https://laohu8.com/S/INTC\">Intel</a>, said demand for its equipment remained strong.</p>\n<p>\"Everybody is working extremely hard, us and our suppliers, to actually produce ... more machines,\" ASML Chief Executive Officer Peter Wennink said.</p>\n<p>Buoyant sales of consumer electronics in the pandemic, stockpiling in <a href=\"https://laohu8.com/S/CAAS\">China</a> and supply problems have created a global shortage of semiconductors that has hit a variety of industries.</p>\n<p>ASML, which reported second quarter net profit up 38% at 1.02 billion euros ($1.2 billion), lifted its 2021 sales growth outlook to 35%.</p>\n<p>Orders for ASML's lithography systems reached 8.3 billion euros in the second quarter, up 75% compared to the end of the first quarter, with orders worth 4.9 billion euros for EUV machines, the extreme ultraviolet systems required to manufacture advanced chips.</p>\n<p>ASML, based in Veldhoven, in the south of the Netherlands, is the dominant maker of lithography systems, enormous machines that focus beams of energy to help map out the tiny circuitry of computer chips and cost up to 200 million euros each.</p>\n<p>ASML said it would buy back 9 billion euros worth of its own shares by the end of 2022, replacing its almost finished 6 billion euro buyback launched last year.</p>\n<p>ASML's share price has risen more than 40% since the start of 2021, reaching an all-time high this month.</p>\n<p>\"I think the future for the industry looks bright. The semiconductor makers currently have a combined sales number of about $500 billion. That could be a trillion dollars by the end of this decade,\" Wennink said.</p>\n<p>The bulk of ASML's sales are to Taiwan and South Korea, with China ranked third and the <a href=\"https://laohu8.com/S/UBNK\">United</a> States fourth.</p>\n<p>\"It's all driven by basically what we are seeing today which is the digital revolution. It's the roll out of 5G and 6G. It's the progress we're making on artificial intelligence, self-driving cars,\" the CEO said.</p>\n<p>($1 = 0.8500 euros)</p>\n<p>(Reporting by Bart Meijer; Editing by Subhranshu Sahu and Edmund Blair)</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ASML rose over 3% in premarket trading, it hikes 2021 sales outlook as chip demand stays strong</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nASML rose over 3% in premarket trading, it hikes 2021 sales outlook as chip demand stays strong\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-21 16:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(July&nbsp;21)&nbsp;<a href=\"https://laohu8.com/S/ASML\">ASML Holding NV</a> rose over 3% in premarket trading, it hikes 2021 sales outlook as chip demand stays strong.</p>\n<p><img src=\"https://static.tigerbbs.com/e5b3b8b29b8d681781a613380a8564f3\" tg-width=\"704\" tg-height=\"486\" referrerpolicy=\"no-referrer\"></p>\n<p>ASML, <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the biggest suppliers to semiconductor companies worldwide, hiked its 2021 sales outlook on Wednesday and announced a new share buyback, as sales soared amid a global computer chip shortage.</p>\n<p>The Dutch company, which services all major chip makers, such as TSMC, Samsung and <a href=\"https://laohu8.com/S/INTC\">Intel</a>, said demand for its equipment remained strong.</p>\n<p>\"Everybody is working extremely hard, us and our suppliers, to actually produce ... more machines,\" ASML Chief Executive Officer Peter Wennink said.</p>\n<p>Buoyant sales of consumer electronics in the pandemic, stockpiling in <a href=\"https://laohu8.com/S/CAAS\">China</a> and supply problems have created a global shortage of semiconductors that has hit a variety of industries.</p>\n<p>ASML, which reported second quarter net profit up 38% at 1.02 billion euros ($1.2 billion), lifted its 2021 sales growth outlook to 35%.</p>\n<p>Orders for ASML's lithography systems reached 8.3 billion euros in the second quarter, up 75% compared to the end of the first quarter, with orders worth 4.9 billion euros for EUV machines, the extreme ultraviolet systems required to manufacture advanced chips.</p>\n<p>ASML, based in Veldhoven, in the south of the Netherlands, is the dominant maker of lithography systems, enormous machines that focus beams of energy to help map out the tiny circuitry of computer chips and cost up to 200 million euros each.</p>\n<p>ASML said it would buy back 9 billion euros worth of its own shares by the end of 2022, replacing its almost finished 6 billion euro buyback launched last year.</p>\n<p>ASML's share price has risen more than 40% since the start of 2021, reaching an all-time high this month.</p>\n<p>\"I think the future for the industry looks bright. The semiconductor makers currently have a combined sales number of about $500 billion. That could be a trillion dollars by the end of this decade,\" Wennink said.</p>\n<p>The bulk of ASML's sales are to Taiwan and South Korea, with China ranked third and the <a href=\"https://laohu8.com/S/UBNK\">United</a> States fourth.</p>\n<p>\"It's all driven by basically what we are seeing today which is the digital revolution. It's the roll out of 5G and 6G. It's the progress we're making on artificial intelligence, self-driving cars,\" the CEO said.</p>\n<p>($1 = 0.8500 euros)</p>\n<p>(Reporting by Bart Meijer; Editing by Subhranshu Sahu and Edmund Blair)</p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ASML":"阿斯麦"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1179602567","content_text":"(July 21) ASML Holding NV rose over 3% in premarket trading, it hikes 2021 sales outlook as chip demand stays strong.\n\nASML, one of the biggest suppliers to semiconductor companies worldwide, hiked its 2021 sales outlook on Wednesday and announced a new share buyback, as sales soared amid a global computer chip shortage.\nThe Dutch company, which services all major chip makers, such as TSMC, Samsung and Intel, said demand for its equipment remained strong.\n\"Everybody is working extremely hard, us and our suppliers, to actually produce ... more machines,\" ASML Chief Executive Officer Peter Wennink said.\nBuoyant sales of consumer electronics in the pandemic, stockpiling in China and supply problems have created a global shortage of semiconductors that has hit a variety of industries.\nASML, which reported second quarter net profit up 38% at 1.02 billion euros ($1.2 billion), lifted its 2021 sales growth outlook to 35%.\nOrders for ASML's lithography systems reached 8.3 billion euros in the second quarter, up 75% compared to the end of the first quarter, with orders worth 4.9 billion euros for EUV machines, the extreme ultraviolet systems required to manufacture advanced chips.\nASML, based in Veldhoven, in the south of the Netherlands, is the dominant maker of lithography systems, enormous machines that focus beams of energy to help map out the tiny circuitry of computer chips and cost up to 200 million euros each.\nASML said it would buy back 9 billion euros worth of its own shares by the end of 2022, replacing its almost finished 6 billion euro buyback launched last year.\nASML's share price has risen more than 40% since the start of 2021, reaching an all-time high this month.\n\"I think the future for the industry looks bright. The semiconductor makers currently have a combined sales number of about $500 billion. That could be a trillion dollars by the end of this decade,\" Wennink said.\nThe bulk of ASML's sales are to Taiwan and South Korea, with China ranked third and the United States fourth.\n\"It's all driven by basically what we are seeing today which is the digital revolution. It's the roll out of 5G and 6G. It's the progress we're making on artificial intelligence, self-driving cars,\" the CEO said.\n($1 = 0.8500 euros)\n(Reporting by Bart Meijer; Editing by Subhranshu Sahu and Edmund Blair)","news_type":1},"isVote":1,"tweetType":1,"viewCount":82,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":146947326,"gmtCreate":1626051486165,"gmtModify":1633930670619,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/146947326","repostId":"1114863871","repostType":4,"isVote":1,"tweetType":1,"viewCount":71,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":143699932,"gmtCreate":1625790442526,"gmtModify":1633937348609,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/143699932","repostId":"1195657546","repostType":4,"repost":{"id":"1195657546","kind":"news","pubTimestamp":1625785913,"share":"https://www.laohu8.com/m/news/1195657546?lang=&edition=full","pubTime":"2021-07-09 07:11","market":"us","language":"en","title":"Stocks making the biggest moves after hours: Levi Strauss, General Motors, Accolade and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1195657546","media":"CNBC","summary":"Check out the companies making headlines after the bell Thursday:\nLevi Strauss— Shares of Levi Strau","content":"<div>\n<p>Check out the companies making headlines after the bell Thursday:\nLevi Strauss— Shares of Levi Strauss added 3.2% after the retailer crushed Wall Street expectations in itsfiscal second-quarter ...</p>\n\n<a href=\"https://www.cnbc.com/2021/07/08/stocks-making-the-biggest-moves-after-hours-levi-strauss-gm-accolade.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stocks making the biggest moves after hours: Levi Strauss, General Motors, Accolade and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStocks making the biggest moves after hours: Levi Strauss, General Motors, Accolade and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-09 07:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/07/08/stocks-making-the-biggest-moves-after-hours-levi-strauss-gm-accolade.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Check out the companies making headlines after the bell Thursday:\nLevi Strauss— Shares of Levi Strauss added 3.2% after the retailer crushed Wall Street expectations in itsfiscal second-quarter ...</p>\n\n<a href=\"https://www.cnbc.com/2021/07/08/stocks-making-the-biggest-moves-after-hours-levi-strauss-gm-accolade.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ACCD":"Accolade, Inc.","GM":"通用汽车","BGC":"BGC GROUP"},"source_url":"https://www.cnbc.com/2021/07/08/stocks-making-the-biggest-moves-after-hours-levi-strauss-gm-accolade.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1195657546","content_text":"Check out the companies making headlines after the bell Thursday:\nLevi Strauss— Shares of Levi Strauss added 3.2% after the retailer crushed Wall Street expectations in itsfiscal second-quarter results. Levi reported adjusted earnings of 23 cents per share on revenue of $1.28 billion. Analysts expected earnings of 9 cents per share on revenue of $1.21 billion, according to Refinitiv.\nGeneral Motors— General Motors shares gained 1.3% after Wedbush initiated coverage of the stock with an outperform rating and $85 price target. That target implies an upside of more than 51% from Thursday's close. \"CEO Mary Barra along with other key executives has led the legacy auto company back to the top of the auto industry in the United States,\" Wedbush's Dan Ives said in a note.\nPriceSmart— Shares of PriceSmart rose 2.4% in thin trading on the back of the warehouse club operator’s third-quarter earnings report. PriceSmart posted earnings of 73 cents per share, compared with a FactSet estimate of 65 cents per share expectation.\nAccolade— Accolade shares added 1.2% in low-volume trading following after the company released its latest quarterly numbers. The health-care technology company reported revenue of of $59.5 million versus analysts’ $55.8 million estimate, according to FactSet. Accolade also posted a smaller-than-expected EBITDA loss.","news_type":1},"isVote":1,"tweetType":1,"viewCount":54,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":839405972,"gmtCreate":1629170722496,"gmtModify":1633686841329,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"I am holding","listText":"I am holding","text":"I am holding","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/839405972","repostId":"2159222279","repostType":4,"isVote":1,"tweetType":1,"viewCount":107,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":179135320,"gmtCreate":1626491944060,"gmtModify":1633926269301,"author":{"id":"3582507638581570","authorId":"3582507638581570","name":"Carolinetsh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582507638581570","authorIdStr":"3582507638581570"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/179135320","repostId":"2152168594","repostType":4,"repost":{"id":"2152168594","kind":"news","pubTimestamp":1626488760,"share":"https://www.laohu8.com/m/news/2152168594?lang=&edition=full","pubTime":"2021-07-17 10:26","market":"us","language":"en","title":"Apple Stock: Next Stop, $175?","url":"https://stock-news.laohu8.com/highlight/detail?id=2152168594","media":"TipRanks","summary":"So, Apple  is having a bad year, you say?With shares hitting an all-time high this week and the gap in performance narrowing over the past month, that conversation can now be put to rest.The uptick has coincided with reports Apple has boosted the production rate of its iPhones, instructing manufacturers to build 90 million iPhones this year, a 20% increase on the 75 million units it produced last year.The renewed optimism in all things Apple is not surprising to J.P. Morgan’s Samik Chatterjee. T","content":"<div>\n<p>So, Apple (AAPL) is having a bad year, you say? Not long ago, the talk on Wall Street was all about the tech giant’s uncharacteristically underperforming stock, especially when compared to some of the...</p>\n\n<a href=\"https://finance.yahoo.com/news/apple-stock-next-stop-175-135700668.html\">Web Link</a>\n\n</div>\n","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple Stock: Next Stop, $175?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple Stock: Next Stop, $175?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-17 10:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/apple-stock-next-stop-175-135700668.html><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>So, Apple (AAPL) is having a bad year, you say? Not long ago, the talk on Wall Street was all about the tech giant’s uncharacteristically underperforming stock, especially when compared to some of the...</p>\n\n<a href=\"https://finance.yahoo.com/news/apple-stock-next-stop-175-135700668.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"03086":"华夏纳指","AAPL":"苹果","09086":"华夏纳指-U"},"source_url":"https://finance.yahoo.com/news/apple-stock-next-stop-175-135700668.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2152168594","content_text":"So, Apple (AAPL) is having a bad year, you say? Not long ago, the talk on Wall Street was all about the tech giant’s uncharacteristically underperforming stock, especially when compared to some of the other mega-caps’ displays in 2021.\nWith shares hitting an all-time high this week and the gap in performance narrowing over the past month, that conversation can now be put to rest.\nThe uptick has coincided with reports Apple has boosted the production rate of its iPhones, instructing manufacturers to build 90 million iPhones this year, a 20% increase on the 75 million units it produced last year.\nThe renewed optimism in all things Apple is not surprising to J.P. Morgan’s Samik Chatterjee. The analyst recently told investors Apple is well set up to outperform in 2H21. In fact, the growing confidence means Chatterjee has added Apple to the firm’s Analyst Focus List as “a Growth idea.”\n“The recent momentum led by better market share, drives us to also estimate higher sustainable volumes in future quarters, leading us to see a path to Apple outperforming investor expectations over a longer time horizon rather than just the upcoming earnings print,” the 5-star analyst said, confirming Apple is also a Top Pick.\nTo reflect the increase in build rates, Chatterjee has “modestly” increased iPhone volume expectations, but of more importance to the analyst is the “path to upside” for the shares in the medium-term.\nThis is because of the potential for better iPhone 12 sales but also due to what Chatterjee considers are low expectations from the iPhone 13’s fall launch, which could create “another leg to the upside opportunity.”\nIt’s a potent mix which is given additional allure with the launch of the iPhone SE3 next year and means Apple can “not only pleasantly surprise with a more robust iPhone 13 cycle, but also has the opportunity to drive material upside to consensus expectations for FY22.”\nTo this end, Chatterjee rates Apple shares an Overweight (i.e. Buy), while slightly lifting the price target from $170 to $175. The revised figure implying shares will add 19.5% from current levels.\nSo, that’s J.P. Morgan’s view, what does the rest of the Street have in mind for Apple? Based on 20 Buys, 5 Holds and 2 Sells, the stock currently has a Moderate Buy consensus rating. The forecast is for shares to appreciate by 8% over the coming months, given the average price target clocks in at $158.62.\nTo find good ideas for tech stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.","news_type":1},"isVote":1,"tweetType":1,"viewCount":3,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}